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Metabolism, Excretion and Toxicity 
ANOVA Analysis of Variance 
ATP Adenosine triphosphate 
ALP Alkaline phosphatase 
BSA Bovine serum albumin 
CAT Catalase 
CADD Computer Aided Drug Design 
COX-2 Cyclooxygenase-2 
DMH 1,2-Dimethyl hydrazine 
DNA Deoxyribonucleic acid 
DTNB 5,5- Dithiobis (2-Nitrobenzoic acid) 
XP Extra-precision 
EDTA Ethylene diamine tetra acetic acid 
GLIDE Grid-based Ligand Docking with 
Energetics 
GPx Glutathione peroxidase 
GSH Glutathione reduced 
g Gram 
FBS Foetal bovine serum 
Hb Haemoglobin 
H2O2 Hydrogen peroxide 
    IDC Invasive (or Infiltrating) ductal 
carcinoma 
 ILC Invasive (or Infiltrating) lobular 
carcinoma 
IBC Inflammatory breast cancer 
IAEC Institution of Animal Ethical Committee 
i.p Intra peritoneal 
LCIS Lobular carcinoma in situ 
LPO Lipid peroxidation 
Abbreviations 
 
Dept. of Pharmacology, KMCH College of Pharmacy 
 
L Litre 
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Na CMC Sodium carboxy methyl cellulose 
p.o Per oral 
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PDB Protein Data Bank 
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TRIS Tris ( hydroxymethyl) amino 
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U/ml Units per millilitre 
VEGF Vascular Endothelial Growth Factor 
µL Microlitre 
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ABSTRACT 
 
The present study was designed to synthesize and investigate the cytotoxic and therapeutic 
effects of Pyrazolo benzpyridazine derivatives against DMH induced colon carcinoma in 
Sprague Dawley(SD) Rats. Docking studies were performed with VEGFR2 in order to 
understand the interaction of ligand with targeted receptor. Based on docking scores and 
chemical availability, 6 compounds were synthesised and confirmed through spectral 
analytical techniques (UV, IR, NMR and MASS). DPPH and ABTS antioxidant activity were 
performed in synthesised compounds and they showed good antioxidant activity. They were 
screened against Human Colon Cancer (HT29) cell line. Out of these, Pz-5 was found to be 
potent with promising IC50 Value of 27.64 µM against HT29 cell line. From the acute toxicity 
studies conducted on Female Wistar rats, the compound PZ-5 showed to be safe upto the dose 
of 2000mg/kg. Further in vivo studies was carried out for PZ-5 by inducing the colon 
carcinoma with the chemical carcinogen DMH(20mg/kg) for 4months in SD Rats and 
therapeutic effect of the compound PZ-5 on various haematological and enzymatic 
parameters were studied by treating with two dose levels (100mg/kg,200mg/kg) for 30days. 
The compound PZ-5 moderately increased the in vivo antioxidant levels like Reduced 
Glutathione (GSH), Glutathione peroxidise (GPx), Catalase (CAT), Super oxide dismutase 
(SOD), and Total protein, and reduced the lipid peroxidation in a dose dependent manner. 
The blood cell count, serum ALP, TCA cycle enzyme succinate dehydrogenase levels were 
also moderately altered on treatment with the compound at a dose of 200mg/kg as compared 
with negative control group in a dose dependent manner. These results suggested that the 
compound has a significant cytotoxic activity against colon cancer.        
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1. INTRODUCTION 
Among the entire diseases, cancer ranks high as a major killer worldwide.
[1] 
Cancers 
are a large family of diseases that includes the abnormal cell growth with the potential 
to invade or spread to other parts of the body
[2]
. The term cancer derives from the 
Greek word (Karkinoma) for crab, by Hippocrates used to describe the appendage-
like projections extending from tumours. Cancer refers to a disease of cells that show 
unlimited proliferation, dedifferentiation, invasiveness and the ability to metastatis 
.The branch of science dealing with the study of  tumours or neoplasms is known as 
oncology.
 [3]
 
EPIDEMIOLOGY OF CANCER
 [3] 
In 2012 about 14.1 million of new cancer cases occurred globally. It accounts about 
8.2 million deaths or 14.6% among all human deaths. The most common category of 
cancer in males are  prostate cancer, colorectal cancer, lung cancer, and stomach 
cancer, and in females, the most common types are lung cancer ,breast cancer, 
colorectal cancer, and cervical cancer. In children, brain tumors and acute 
lymphoblastic leukaemia  are most common except in Africa where non-Hodgkin 
lymphoma appears more often. In 2012, about 165,000 children under the age of 15 
years were diagnosed with cancer. The threat of cancer increases appreciably with age 
and may occur generally in developed countries.
 [3]
 
THE SIX HALL MARKS OF CANCER
[3]
 
1. Cell growth and multiplication without the proper signals  
2. Continuous cell division and growth even when there are signals bring to an 
end 
3. Avoidance of the programmed cell death 
4. Unlimited number of cell divisions 
5. Promoting blood vessel construction 
6. Invasion of tissue and development of metastases[3] 
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TYPES OF TUMOURS 
[4] 
Tumors may be benign or malignant. Benign tumours are generally localized, slow 
growing, resemble normal cells, and are usually not harmful. The terms cancer or 
malignant neoplasm or malignant tumour are synonymous. They proliferate rapidly, 
manifest dedifferentiation, invasiveness, and the capacity to metastasis. They cause 
damage on the surrounding cells and are harmful if left untreated. 
Cancers are classified based on  
 The Origin of the tumor.  
These types include: 
 Benign tumours names usually end with ―oma‖, for example Papilloma (from 
surface epithelium), Adenoma (from glandular epithelium), Melanoma (from 
pigment cells), Myoma (from muscle tissue), Fibroma (from fibrous tissue) 
Neurofibroma (from nerve sheath) and Aleiomyoma  (from smooth  muscle cells) 
,etc. 
 Malignant neoplasms are either Solid tumours or Haematological malignancies. 
 Carcinoma: Derived from epithelial cells, most common cancers, mainly in the 
aged, in the breast, prostate, lung, pancreas, and colon. 
 Blastoma: Derived from immature "precursor" cells or embryonic tissue and are 
more common in children than in older adults. 
  Leukemia and lymphoma: These two types of tumours arise from hematopoietic 
(blood-forming) cells and be likely to mature in the blood and lymph nodes, 
respectively. In children, leukemia is the most common type of cancer accounts 
for about 30%. 
 Germ cell tumor: Derived from pluripotent cells, occurs in the ovary or 
the testicle (dysgerminoma and seminoma, respectively). 
 Sarcoma: Arises from connective tissue (i.e. nerve, cartilage, bone, fat ), which 
develops from cells originating in mesenchymal cells outer the bone marrow. 
Types of cancer classified by body system 
 Cancer has the potential to affect each organ in the body. The cells inside the 
malignant tumours have the capability to attack surrounding tissues and organs, thus 
spreading the disease. 
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1. Blood cancer: These cancers are also known as leukemia or lymphoma.   
 Leukemia. 
 Waldenstrom's Macroglobulinemia  
 Lymphoma.   
 Multiple Myeloma  
2. Bone cancer: It is rare type of cancer. It affects both adults and children. Common 
type of cancer are  
 Ewings sarcoma  
 Osteosarcoma  
3. Brain cancer: Brain cancers are malignant or benign. They affect both children 
and adults. It spread only in brain. 
 Brain tumour  
 Brain Stem Glioma, Childhood  
 Cerebellar Astrocytoma, Childhood  
 Cerebral Astrocytoma / Malignant Glioma, Childhood 
 Ependymoma, Childhood 
 Medulloblastoma, Childhood  
4. Breast cancer: It is a common type of cancer, mainly affect females. Common 
types of breast cancers are  
 Ductal carcinoma in situ  
 Lobular carcinoma in situ 
 Inflammatory breast cancer  
 Paget‘s disease of the nipple  
5. Digestive cancers: Also known as gastrointestinal cancers. It is a broad group of 
cancer that affects all the parts from oesophagus to anus. All cancers are specific 
and have its own symptoms. They are  
 Anal cancer  
 Bile Duct Cancer, Extra hepatic  
 Carcinoid Tumour, Gastrointestinal 
 Colon Cancer 
 Gall bladder Cancer  
 Oesophageal Cancer 
 Liver Cancer 
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 Pancreatic Cancer  
 Rectal Cancer   
 Small Intestine Cancer   
 Stomach (Gastric) Cancer   
6. Endocrine cancers: The most common type is thyroid cancer. The other types are  
 Adrenocortical Carcinoma  
 Islet Cell Carcinoma (Endocrine Pancreas)  
 Parathyroid Cancer 
 Pheochromocytoma  
 Pituitary Tumour  
 Thyroid Cancer   
7. Eye Cancer: It will affect both children and adults.  
 Melanoma, Intraocular  
 Retinoblastoma   
8. Genitourinary cancers: It affects the male genitalia and urinary tract.  
 Bladder Cancer  
 Kidney (Renal Cell) Cancer 
 Penile Cancer  
 Prostate Cancer  
 Renal Pelvis and Ureter Cancer, Transitional Cell  
 Testicular Cancer  
 Urethral Cancer 
 Wilms' Tumour and Other Childhood Kidney Tumours   
9. Gynaecological cancers: It will affect the organs of female reproductive system. 
 Cervical Cancer  
 Endometrial Cancer  
 Ovarian Cancer  
 Vaginal Cancer   
 Vulvar Cancer     
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10. Head and  Neck cancers: This cancer affects the moist surface of neck and head. 
Cigarette smoking plays important role in this cancer. 
 Hypo pharyngeal Cancer  
 Laryngeal Cancer  
 Lip and Oral Cancer  
 Metastatic Squamous Neck Cancer  
 Nasopharyngeal Cancer  
 Oropharyngeal Cancer  
 Paranasal Sinus and Nasal Cavity Cancer 
 Parathyroid Cancer 
 Salivary Gland Cancer   
11. Respiratory cancers: Cigarette smoking is the main reason for cancer affecting 
respiratory system.    
 Lung Cancer 
 Malignant Mesothelioma 
 Thymoma and Thymic Carcinoma   
12.Skin cancer: The UV rays from sun are one of the main reasons for skin cancer. 
 Cutaneous T-Cell Lymphoma 
 Melanoma 
 Non-Melanoma Skin Cancer  
SYMPTOMS OF CANCER 
[5]
 
It is important to note that some types of cancer do not present any symptoms until 
they are in advanced stages. Because of this reason cancer screening and its risk 
assessment are vital for cancer prevention and its early detection. The common 
symptoms are, 
 Persistent fatigue 
Fatigue is one of the most commonly experienced cancer symptoms. It is usually 
more common in the advanced conditions, but still occurs in the early stages of some 
cancers. Fatigue is a symptom of both malignant and non malignant conditions. 
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 Weight loss 
It can be a red flag for many illnesses, including cancer. This type of weight loss can 
occur with or without loss of appetite. Weight loss can be a symptom of cancer, but is 
also a symptom of many other illnesses, too. 
 Pain 
Typically, pain is not an early symptom of cancer, except in some cancer types like 
those that are spread to the bone. Pain generally occurs when cancer spreads and 
begins to affect other organs and nerves. Lower back pain is a cancer symptom that is 
associated with ovarian cancer and colon cancer. Shoulder pain can also be a 
symptom of lung cancer. Pain in the form of headaches can be associated with brain 
tumours (malignant and benign). Stomach pains can be related to types of cancer like 
stomach and pancreatic cancer. 
 Fever 
Fever is a very non-specific symptom of many mild to severe conditions, including 
cancer. Fevers are commonly associated with types of cancers that affect the blood, 
like leukemia and lymphoma, but are also common in people who have metastasis 
cancer. 
 Bowel changes 
The symptoms like constipation, diarrhoea, blood in stools, gas, thinner stools, or 
overall changes in bowel habits are commonly associated with colon cancer, but are 
also related to other cancer types. 
 Chronic cough 
A persistent, new cough or that becomes worse needs to be evaluated by a doctor. A 
chronic cough with blood and mucus can be a symptom of lung cancer.These are 
vague symptoms of cancers and they can also be experienced by most people with 
cancer at various stages of their disease, but are also linked to many other non-
cancerous conditions. 
 Based on the location of the tumour the symptoms of cancer metastasis is 
depicted in the figure 1.
[3]
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Fig.1 shows the Symptoms of cancer metastasis based on location of tumour 
 
 
ETIOLOGY OF CANCER 
[3]
  
Cancer is a diverse class of disease which varies widely in their causes and 
biology. Among all known cancers, the common thread is the attainment of 
abnormalities in the genetic material of the cancer cell and its progeny.  
The cancer pathogenesis can be categorized into three areas of interest. 
1. The agents or events which effect or assist inherited changes in cells intended to 
become cancer. 
2. It is significant to uncover the exact nature of the inherited damage, and the genes 
which are affected by it.  
3. As a result of these genetic changes on the cell biology, both in initiating the 
essential properties of a cancer cell, and in facilitating further genetic events, leads to 
further development of the tumor. 
Chemicals 
Exposure to certain substances called carcinogens for example,  
1. Tobacco smoking causes 90% of lung cancer which also results cancer in the head, 
larynx, head, neck, bladder, stomach, kidney, esophagus and pancreas. 
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2. Alcohol exposure results in cancer of the liver and of the digestive tract.  
3. Cancer related substance at work. 
In every year, at least 200,000 people die worldwide from cancer related to their 
workplaces.  
Diet and exercise 
 About 30-35% of cancer deaths, are related to diet, physical inactivity, 
and obesity. 
  Excess body weight and  is associated with the progression of major types of 
cancer and is a factor in 14–20% of all cancer deaths.  
 Some specific foods are linked to specific cancers. For example, gastric 
cancer is more common in Japan due to its high-salt diet and colon cancer is 
more common in the United States.  
Infection 
Oncovirus that can cause cancer include  
 Human papillomavirus (cervical carcinoma), 
 Epstein–Barr virus (B-cell lymphoproliferative disease and nasopharyngeal 
carcinoma), 
 Kaposi's sarcoma herpes virus (Kaposi's sarcoma and primary effusion 
lymphomas), 
 Hepatitis B and hepatitis C viruses (hepatocellular carcinoma), and  
 Human T-cell leukemia virus-1 (T-cell leukemias).  
 Bacterial infection may also induce cancer include Helicobacter pylori-
induced gastric carcinoma.  
Radiation 
 It includes both ionizing radiation and non-ionizing ultraviolet radiation . 
 Sources of ionizing radiation include medical imaging and radon gas.  
  Prolonged exposure to non-ionisng ultraviolet radiation from the sun can lead 
to melanoma and other skin malignancies.  
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Heredity 
 The majority of cancers are non-hereditary ("sporadic cancers"). 
 Hereditary cancers are mainly caused by an inherited genetic defect. 
 Certain inherited mutations in the genes BRCA1 and BRCA2 with a more than 
75% risk of breast cancer and ovarian cancer, and hereditary nonpolyposis 
colorectal cancer (HNPCC or Lynch syndrome), which is present in about 3% of 
people with colorectal cancer, among others. 
Physical agents 
  Prolonged exposure to asbestos, naturally occurring mineral fibers that are a 
major cause of  mesothelioma, which is a cancer of the serous membrane 
surrounding the lungs.  
Hormone 
  Insulin-like growth factors and their binding proteins play a major role in cancer 
cell proliferation, differentiation and apoptosis, suggesting possible involvement 
in carcinogenesis.  
 Hormones are important agents in sex-related cancers, such as cancer of the 
breast, endometrium, prostate, ovary, and testis, and also of thyroid 
cancer and bone cancer.   
PATHOPHYSIOLOGY 
[9] 
Cancers are caused by a sequence of mutations, which causes the variation of the 
behavior of the cells. Normal cell mutated into cancer cell, cause the failure of 
regulation of cell growth and the carcinogenesis process is depicted in figure 2. 
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Figure  2: Carcinogenesis  process 
 
                                                  
 THE GENESIS OF A CANCER CELL 
[9] 
A normal cell turns into a cancer cell because of one or more mutations in its DNA, 
which can be inherited or acquired. The cancer progression is a complex multistage 
events, involving not only more than one genetic change but usually also 
other,epigenetic factors (co-carcinogen and tumour promotor effects, etc.) that are 
indirectly produces cancer by genetic mutations. 
 Two major catagories of genetic change that lead  to cancer: 
 The activation of proto-oncogene to oncogenes 
 The activation of tumour suppressor genes. 
These changes are a result of point mutations, gene amplication or 
chromosomal translocation, often due to the action of certain viruses or 
chemical carcinogenes. 
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a. Activation of proto-oncogenes to oncogenes 
Proto-oncogenes are genes that normally control cell division, apoptosis and 
differentiation but which can be converted to oncogenes by viral or carcinogen 
action.These include : 
 Her2/neu(breast cancer) 
 Bcr-abl (chronic myelocytic leukemia,B-cell acute lymphocytic leukemia) 
Oncogenes are classified based on the functional and biochemical properties of 
protein products of  their proto-oncogenes. 
1. Growth factor 
2. Growth factor receptor 
3. Signal transducers
 
4. Transcription factor
 
5. Other including programmed cell death regulators
 
b. Inactivation of tumour supressor genes 
Normal cells contain genes that have the ability to supress malignant change termed 
tumour suppressor genes and the mutations of these genes are involved in many 
different cancers. The loss of function of tumour suppressor genes can be the 
important event in carcinogenesis. 
Eg:  
RB (Retinoblastoma) gene mutations results in Retinoblastoma, Bone, Breast, Lung, 
Prostate and Bladder cancers. 
P53 gene mutations leads to the development of Breast,Colon,Leukemia and soft 
tissue sarcomas. 
BRCA 1 gene located in chromosome 17, mutation associated with high risk of 
developing Breast cancer. 
About 30 tumour suppressor genes and dominant oncogenes have been identified. 
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THE SPECIAL CHARACTERISTICS OF CANCER CELLS 
[7] 
 UNCONTROLLED PROLIFERATION 
The proliferation of cancer cells is not controlled by the processes that normally 
regulate cell division and tissue growth. Inactivation  of  tumour suppressor genes or 
transformation of proto-oncogenes into oncogenes can confer autonomy of growth on 
a cell and thus result in uncontrolled proliferation by producing changes in: 
 Growth factors and their receptors. 
 The growth factor pathways-the cystolic and nuclear transducers. 
 The cell cycle transducers –eg. Cyclins, cyclin-dependent kinases(cdks) or the 
cdk inhibitors 
 The apoptic mechanisms that normally dispose of abnormal cells. 
 Telomerase expression  
 Local blood vessels, resulting from tumour-directed angiogenesis. 
 
 Apoptosis and the genesis of a cancer cell  
Apoptosis is programmed cell death and anti-apoptotic genetic lesions are necessary 
for cancer to develop. In fact development of resistance to apoptosis is a hallmark of 
cancer. Decreased apoptosis can be brought about by inactivation of proapototic 
factors or by activation of anti-apoptotic factors. 
 Telomerase expression  
Telomeres are specialized structures that cap the ends of chromosomes like the small 
metal tubes on the end of shoelaces protecting them from degradation, rearrangement 
and fusion with other chromosomes. Germline cells, stem cells and the proliferating 
cells of the gastrointestinal tract, bone marrow ,etc. express telomerase-an enzyme 
that maintains and stabilizes telomeres. Most fully differentiated somatic cells do not 
express telomerase, but about 95% of late-stage malignant tumours do express it and 
it is suggested that this enzyme can confer ‗immortality‘ on a cancer cell. 
 The control of tumour-related blood vessels 
The actual growth of a solid tumour depends on the development of its own blood 
supply. Tumours 1-2 mm in diameter can receive nutrients by diffusion, but any 
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further expansion requires the development of new blood vessels angiogenesis. 
Angiogenesis occurs in response to growth factors produced by the growing tumours. 
 DEDIFFERENTIATION AND LOSS OF FUNCTION 
One of the main characteristics of cancer cells is that they differentiate to a varying 
degree in different tumours. In general, poorly differentiated cancers multiply faster 
and have a poor prognosis than well-differentiated cancers. 
 INVASIVENESS 
Normal cells are not found outside their ‗designated‘ tissue of origin. For example, 
liver cells are not found in the bladder, and pancreatic cells are not found in the testis. 
This is because during differentiation and the growth of tissues and organs, normal 
cells develop certain spatial relationships are maintained by various tissue-specific 
survival factors anti-apoptotic factors. Any cells that escape accidentally lose these 
survival signals and undergo apoptosis. 
 METASTASIS 
Metastasis is the spread of cancer to other locations in the body by local spread, 
lymphatic spread to regional lymph nodes or by blood (haematogenous spread) to 
distant sites. The new tumors are called metastatic tumors, while the original is called 
the primary tumor. The symptoms of metastatic cancers depend on the location of the 
tumor, and can include enlarged lymph nodes (which can be felt or sometimes seen 
under the skin and are typically hard), enlarged liver or enlarged spleen, which can be 
felt in the abdomen, pain or fracture of affected bones, and neurological symptoms. 
Almost all cancers can metastasize. Most cancer deaths are due to cancer that has 
spread from  its primary site to other organs (metastasized).  
 DIAGNOSIS 
Most cancers are initially identified either because of the appearance of signs or 
symptoms or through screening. Neither of these lead to a definitive diagnosis, which 
requires the examination of a tissue sample by a pathologist. These commonly 
include blood tests, X-rays, CT scans and endoscopy. 
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COLON CANCER 
[6] 
 
Globally, colorectal cancer is the third most common type of cancer making up about 
10% of all cases. In 2012, there were 1.4 million new cases and 694,000 deaths from 
the disease. It is more common in developed countries, where more than 65% of cases 
are found. It is less common in women than men. Colorectal cancer is the fourth most 
common cancer in both men and women in the United States. Most colorectal cancers 
grow slowly over several years, and about 1 in 20 people develop colorectal 
cancer.Due to early screening  and improved treatments, survivorship has increased 
over the past 20 years. 
ANATOMY OF COLON 
[3,6] 
The large intestine, also called the colon or the large bowel, is the last part of 
the digestive system in vertebrates.The ileum (last part of the small intestine) connects 
to the cecum (first part of the colon) in the lower right abdomen. The rest of the colon 
is divided into four parts and the anatomy of colon is shown in figure 3.They are: 
• The ascending colon travels up the right side of the abdomen. 
• The transverse colon runs across the abdomen. 
• The descending colon travels down the left abdomen. 
• The sigmoid colon is a short curving of the colon, just before the rectum.  
The length of the adult human colon is, on average, for women 155 cm (range of 80 to 
214 cm) and for men 166 cm (range of 80 to 313 cm). The average inner 
circumference of sections of the colon in centimeters (with ranges in parentheses) are 
cecum 8.7 (8.0-10.5), ascending colon 6.6 (6.0-7.0), transverse colon 5.8 (5.0-6.5), 
descending/sigmoid colon 6.3 (6.0-6.8) and rectum near rectal/sigmoid junction 5.7 
(4.5-7.5). 
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Figure 3: Anatomy of colon 
 
 
 
PHYSIOLOGY OF COLON 
[6] 
The colon removes water, salt, and some nutrients forming stool. Muscles line the 
colon's walls, squeezing its contents along. Billions of bacteria coat the colon and its 
contents, living in a healthy balance with the body. It 
extracts water and salt from solid wastes before they are eliminated from the body and 
is the site in which flora-aided (largely bacterial) fermentation of unabsorbed material 
occurs. Unlike the small intestinethe colon does not play a major role in absorption of 
foods and nutrients. About 1.5 litres or 45 ounces of water arrives in the colon each 
day.
[6] 
COLON CANCER 
[6,3] 
Colorectal cancer is the development of cancer in the colon or rectum (parts of 
the large intestine). If the cancer began in the colon, which is the first four to five feet 
of the large intestine, it may be referred to as colon cancer. If the cancer began in the 
rectum, which is the last several inches of the large intestine leading to the anus, it is 
called rectal cancer. Colorectal cancer starts in the inner lining of the colon and/or 
rectum, slowly growing through some or all of its layers. It typically starts as a growth 
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of tissue called a polyp. A particular type of polyp, called an adenoma, can then 
develop into cancer..  
Types of colorectal cancer 
[6] 
 Adenocarcinoma   
 Gastrointestinal carcinoid  tumors,  
 Gastrointestinal stromal tumors,  
 Primary colorectal lymphoma,  
 Leiomyosarcoma, 
 Melanoma and 
  Squamous cell carcinoma.  
SIGNS AND SYMPTOMS 
[3,6]
                                          
The signs and symptoms of colorectal cancer depend on the location of the tumor 
(Fig.No.4) in the bowel, and whether it has spread elsewhere in the body (metastasis). 
The classic warning signs include: worsening constipation, blood in the stool, 
decrease in stool caliber (thickness), loss of appetite, loss of weight and feeling tired 
all the time. While rectal bleeding or anemia are high-risk features in those over the 
age of 50, other symptoms including weight loss and change in bowel habit are 
typically only concerning if associated with bleeding.  
Figure 4: Location of tumor
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STAGING OF COLON CANCER 
[6]
  
The staging system most often used for colorectal cancer is the American Joint 
Committee on Cancer (AJCC) TNM system and is shown in figure 5 and in table 1 . 
The TNM system is based on  
  The main (primary) tumor (T) has grown into the wall of the intestine and whether 
it has grown into nearby areas. 
 If the cancer has spread to nearby (regional) lymph nodes (N). Lymph nodes are 
small bean-shaped collections of immune system cells to which cancers often spread 
first. 
 If the cancer has spread (metastasized) to other organs of the body (M). 
                                   Figure 5: Stages of colon cancer 
 
Table 1. The colon cancer staging 
Stage Stage 
grouping 
Stage description 
0 Tis, N0, 
M0 
Earliest stage and also known as carcinoma in situ or 
intramucosal carcinoma (Tis).  
I T1 or T2, 
N0, M0 
The cancer has grown through the muscularis mucosa into the 
submucosa (T1), and muscularis propria (T2). It has not spread 
to nearby lymph nodes (N0) and distant sites (M0). 
IIA T3, N0, M0 The cancer has grown into the outermost layers of the colon or 
rectum but has not gone through them (T3). It has not reached 
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nearby organs like lymph nodes (N0) or to distant sites (M0). 
IIB T4a, N0, 
M0 
The cancer has grown through the wall of the colon or rectum 
but has not grown into other nearby tissues or organs (T4a)like  
lymph nodes (N0) or to distant sites (M0). 
IIC T4b, N0, 
M0 
The cancer is attached to or has grown into other nearby tissues 
or organs (T4b). It has not yet spread to nearby lymph nodes 
(N0) or to distant sites (M0). 
IIIA T1 or T2, 
N1, M0 
It has spread to 1 to 3 nearby lymph nodes (N1a/N1b) or into 
areas of fat near the lymph nodes but not the nodes themselves 
(N1c). It has not spread to distant sites (M0). 
IIIB T3 or T4a, 
N1, M0 
The cancer has grown into the outermost layers of the colon or 
rectum (T3) or through the visceral peritoneum (T4a) but has 
not reached nearby organs. It has spread to 1 to 3 nearby lymph 
nodes (N1a or N1b) or into areas of fat near the lymph nodes 
but not the nodes themselves (N1c). It has not spread to distant 
sites (M0). 
IIIC T4a, N2a, 
M0 
The cancer has grown through the wall of the colon or rectum 
(including the visceral peritoneum) but has not reached nearby 
organs (T4a). It has spread to 4 to 6 nearby lymph nodes (N2a). 
It has not spread to distant sites (M0). 
IVA Any T, 
Any N, 
M1a 
The cancer may or may not have grown through the wall of the 
colon or rectum (Any T). It might or might not have spread to 
nearby lymph nodes. (Any N). It has spread to 1 distant organ 
(such as the liver or lung) or distant set of lymph nodes (M1a). 
IVB Any T, 
Any N, 
M1b 
The cancer might or might not have grown through the wall of 
the colon or rectum. It might or might not have spread to nearby 
lymph nodes. It has spread to more than 1 distant organ (such as 
the liver or lung) or distant set of lymph nodes, or it has spread 
to distant parts of the peritoneum (the lining of the abdominal 
cavity) (M1b). 
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COLORECTAL CANCER GRADES 
[3] 
The scale used for grading colorectal cancers is from 1 to 4. 
 Grade 1 (G1) means the cancer looks much like normal colorectal tissue. 
 Grade 4 (G4) means the cancer looks very abnormal. 
 Grades 2 and 3 (G2 and G3) fall somewhere in between 
The grade is often simplified as either low grade (G1 or G2) or high grade (G3 or 
G4).Low-grade cancers tend to grow and spread more slowly than high-grade cancers. 
ETIOLOGY AND RISK FACTORS OF COLON CANCER 
[3,6] 
The risk factors of Colon cancer includes Diet, smoking, alcohol, lack of physical 
activity, family history of colon cancer and colon polyps, presence of colon polyps, 
exposure to radiation, and even other diseases such as diabetes and obesity.  
DIET 
  A diet high in red, processed meat, while low in fiber increases the risk of colorectal 
cancer. 
DISEASES  
 Inflammatory bowel disease, which includes Crohn's disease and ulcerative 
colitis, can increase the risk of colorectal cancer.  
 Inherited genetic disorders include familial adenomatous polyposis and hereditary 
non-polyposis colon cancer.  
GENETICS 
  A number of genetic syndromes are also associated with higher rates of colorectal 
cancer and The most common of these is hereditary nonpolyposis colorectal 
cancer(HNPCC or Lynch syndrome) which is present in about 3% of people with 
colorectal cancer. Other syndromes include Gardner syndrome and familial 
adenomatous polyposis (FAP).   
 A gene contribute to the potential for metastatic disease in colon cancer 1 
(MACC1), has been associated with the proliferation, invasion and scattering of colon 
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cancer cells in cell culture, and tumor growth and metastasis in mice. MACC1 may be 
a potential target for cancer intervention. 
  Epigenetic factors, such as abnormal DNA methylation of tumor suppressor 
promoters play a role in the development of colorectal cancer. 
PATHOGENESIS OF COLON CANCER 
[3] 
Colorectal cancer is a disease originating from the epithelial cells lining the colon or 
rectum of the gastrointestinal tract, most frequently as a result of mutations in the Wnt 
signaling pathway that increase signaling activity. The mutations can 
be inherited or acquired, and most probably occur in the intestinal crypt stem cell.The 
most commonly mutated gene in all colorectal cancer is the APC gene, which 
produces the APC protein that prevents the accumulation of β-catenin protein. 
Without APC, β-catenin accumulates to high levels and translocates (moves) into the 
nucleus, binds to DNA, and activates the transcription of proto-oncogenes. These 
genes are normally important for stem cell renewal and differentiation, but when 
improperly expressed at high levels, they can cause cancer. While APC is mutated in 
most colon cancers, some cancers have increased β-catenin because of mutations in β-
catenin (CTNNB1) that block its own breakdown, or have mutations in other genes 
with function similar to APC such as AXIN1, AXIN2, TCF7L2, or NKD1. Further 
than the defects in the Wnt signaling pathway, p53 protein, produced by 
the TP53 gene, normally monitors cell division and kills cells if they have Wnt 
pathway defects. Eventually, a cell line acquires a mutation in the TP53 gene and 
transforms the tissue from an benign epithelial tumorinto an invasive epithelial cell 
cancer. 
 Other proteins deactivated in colorectal cancers are TGF-β and DCC (Deleted in 
Colorectal Cancer). TGF-β has a deactivating mutation in at least half of colorectal 
cancers. Sometimes TGF-β is not deactivated, but a downstream protein 
named SMAD is deactivated. DCC commonly has a deleted segment of a 
chromosome in colorectal cancer.  
Some oncogenes are overexpressed in colorectal cancer. For example, genes encoding 
the proteins KRAS, RAF, and PI3K, which normally stimulate the cell to divide in 
response to growth factors, can acquire mutations that result in over-activation of cell 
proliferation. The chronological order of mutations is sometimes important. If a 
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previous APC mutation occurred, a primary KRAS mutation often progresses to 
cancer rather than a self-limiting hyperplastic or borderline lesion. PTEN, a tumor 
suppressor, normally inhibits PI3K, but can sometimes become mutated and 
deactivated.
[31]
 
Genome-scale analysis has discovered that colorectal carcinomas can be categorized 
into hypermutated and non-hypermutated tumor types. In addition to the oncogenic 
and inactivating mutations described for the genes above, non-hypermutated samples 
also contain mutated CTNNB1, FAM123B, SOX9, ATM, and ARID1A. Progressing 
through a distinct set of genetic events, hypermutated tumors display mutated forms 
of ACVR2A, TGFBR2, MSH3, MSH6, SLC9A9, TCF7L2, and BRAF. The common 
theme among these genes, across both tumor types, is their involvement in WNT and 
TGF-β signaling pathways, which results in increased activity of MYC, a central 
player in colorectal cancer.  
TARGETS OF CANCER RESEARCH 
[3] 
Many different targeted therapies have been approved for use in cancer treatment. 
These therapies include hormone therapies, signal transduction inhibitors, gene 
expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, 
and toxin delivery molecules. 
 Hormone therapies slow or stop the growth of hormone-sensitive tumors, which 
require certain hormones to grow. Hormone therapies act by preventing the body 
from producing the hormones or by interfering with the action of the hormones. 
Hormone therapies have been approved for both breast cancer and prostate cancer. 
 Signal transduction inhibitors block the activities of molecules that participate 
insignal transduction, the process by which a cell responds to signals from its 
environment. During this process, once a cell has received a specific signal, the 
signal is relayed within the cell through a series of biochemical reactions that 
ultimately produce the appropriate response(s). In some cancers, 
the malignant cells are stimulated to divide continuously without being prompted 
to do so by external growth factors. Signal transduction inhibitors interfere with 
this inappropriate signaling. 
 Gene expression modulators modify the function of proteins that play a role in 
controlling gene expression. 
Introduction 
 
Department Of Pharmacology, KMCH College Of Pharmacy  22 
 
 Apoptosis inducers cause cancer cells to undergo a process of controlled cell 
death called apoptosis. Apoptosis is one method the body uses to get rid of 
unneeded or abnormal cells, but cancer cells have strategies to avoid apoptosis. 
Apoptosis inducers can get around these strategies to cause the death of cancer 
cells. 
 Angiogenesis inhibitors block the growth of new blood vessels to tumors (a 
process called tumor angiogenesis). A blood supply is necessary for tumors to 
grow beyond a certain size because blood provides the oxygen and nutrients that 
tumors need for continued growth. Treatments that interfere with angiogenesis 
may block tumor growth. Some targeted therapies that inhibit angiogenesis 
interfere with the action ofvascular endothelial growth factor (VEGF), a substance 
that stimulates new blood vessel formation. Other angiogenesis inhibitors target 
other molecules that stimulate new blood vessel growth.  
 Immunotherapies trigger the immune system to destroy cancer cells. Some 
immunotherapies are monoclonal antibodies that recognize specific molecules on 
the surface of cancer cells. Binding of the monoclonal antibody to the target 
molecule results in the immune destruction of cells that express that target 
molecule. Other monoclonal antibodies bind to certain immune cells to help these 
cells better kill cancer cells. 
 Monoclonal antibodies that deliver toxic molecules can cause the death of 
cancer cells specifically. Once the antibody has bound to its target cell, the toxic 
molecule that is linked to the antibody—such as a radioactive substance or a 
poisonous chemical—is taken up by the cell, ultimately killing that cell. The toxin 
will not affect cells that lack the target for the antibody i.e., the vast majority of 
cells in the body. 
PROTEINS 
 Nucleic acids and their precursors 
 Tubulin (Micro tubular protein) 
ENZYMES 
 DNA topoisomerase-I &II 
 5- ∝ Reductase 
 DNA polymerase 
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 Ribonucleoside diphosphate reductase 
 Histone deacetylase(HDAC) 
 Thymidilate synthase 
 Thiomidilate synthatase 
HORMONES 
 Estrogens 
 Testosterone 
 Androgen 
 Progestin 
GENES 
 p53 
 Epidermal Growth Factor Receptor (EGFR) 
 Vascular Growth  Factor Receptor (VEGFR) 
 Oncogene 
DRUGS USED TO TREAT COLORECTAL CANCER 
[6] 
 5-Fluorouracil (5-FU) 
 Capecitabine (Xeloda) 
 Irinotecan (Camptosar) 
 Oxaliplatin (Eloxatin) 
 Trifluridine and tipiracil (Lonsurf) 
 Cetuximab(erbitux) 
 Panitumumab (vectibix®) 
 Bevacizumab (avastin®) 
 Ziv-aflibercept (zaltrap®) 
 Regorafenib (stivarga®) 
 Ramucirumab (cyramza®) 
Often, 2 or more of these drugs are combined to try to make them more effective. 
Sometimes, chemo drugs are given along with a targeted therapy drug. 
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LIMITATION OF CONVENTIONAL THERAPY OF COLORECTAL 
CANCER
 [3] 
Conventional treatment involves varied combinations of surgery, radiation therapy 
and chemotherapy. Radiation and chemotherapy are used if the cancer is untreatable 
or metastasized, and also as follow-up to surgery. In addition, immunotherapy and 
hormone therapy have been used in the treatment of certain forms of melanoma, 
breast and prostate cancers. Chemotherapeutic agents are cytotoxic drugs, which 
affect any cells in the body that are actively dividing. The side-effects can include 
nausea, vomiting, immunosuppression, mucositis, hepatotoxicity, nephrotoxicity, 
memory loss, anemia and even death. Several chemotherapeutic agents also have 
long-term side-effects in major organs such as the heart, lungs, kidneys and central 
nervous system.  
To avoid these adverse effects, conventional chemotherapeutic agents must be 
administered at a safe, but suboptimal dose, which is insufficient to treat the cancer 
satisfactorily in one session. Physicians have attempted to treat cancer using these 
lower doses over a longer period of time, however, this is often ineffective due to the 
development of drug resistance by the cancerous cells. Currently, patients are given 
combination chemotherapy - multiple drugs at various doses to try to circumvent 
these problems. Newer treatments such as tumour vaccines and small-molecule 
therapies avoid many of the side-effects by targeting surface or intracellular proteins 
specific to the cancer being treated. However, these methods can only deal with very 
specific diseases. One such method is targeting Angiogenesis Inhibitors. 
ANGIOGENESIS 
[10] 
Angiogenesis is the process of generating new capillary blood vessels. Unregulated 
angiogenesis may cause different pathologies, such as tumor growth and metastasis . 
A growing tumor needs capillaries to provide nutrients and oxygen and is represented 
in figure 6 and 7. Vascular endothelial growth factor (VEGF), a major mediator of 
vascular permeability and angiogenesis, potentiates microvascular hyperpermeability, 
which can precede and accompany angiogenesis.  
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Figure 6: shows angiogenesis process in a growing tumour cell. 
 
    Figure 7: shows stages at which angiogenesis plays a role in tumor progression 
 
 
The growth factors, angiogenic enzymes, endothelial speciﬁc receptors and the 
adhesion molecules which are involved in the expansion of vasa vasorum are all 
potential therapeutic targets. Amongst growth factors Vascular Endothelial Growth 
Factor (VEGF) is the major pro-angiogenesis factor, which is known to stimulate 
various steps of endothelial angiogenic activity, such as proliferation, migration, 
differentiation into vessel-like tubes. Its identiﬁcation and prominent position in the 
angiogenic  process has converted VEGF to an important therapeutic target. 
Fibroblast growth factors(FGFs) are heparin binding proteins that are also involved in 
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the pathogenesis and subsequent progression of various cancer types such as 
endometrial cancer. 
KEY REGULATORS OF ANGIOGENESIS 
[11,12] 
VEGF is the prototypical proangiogenic molecule, a 45-kDa heparin-binding 
homodimeric glycoprotein and it has been implicated in several steps throughout the 
angiogenesis process. The VEGF family of molecules currently consists of six growth 
factors, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental 
growth factor, and three receptors, including VEGF receptor (VEGFR)-1 (Flt-1), 
VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4) and figure 8 shows the Vascular 
endothelial growth factor (VEGF) family and their receptors. VEGF-A is currently the 
most well-characterized member of the VEGF family and is composed of at least six 
isoforms due to alternative gene splicing . One of the most striking characteristics of 
VEGF is its ability to induce vascular permeability . This enhanced permeability leads 
to subsequent fibrin deposition in the extracellular matrix that can then serve as a 
scaffold for migrating endothelial cells. The three VEGFRs are transmembrane 
tyrosine kinases that are predominantly found on endothelial cells. The activation of 
VEGFR-2 by its ligands results in enhanced permeability of the vasculature and 
increased migration and proliferation of endothelial cells, making it also a major 
target for therapy.     
Figure 8: Vascular endothelial growth factor (VEGF) family and their receptors 
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VEGF family members bind to specific receptor tyrosine kinases VEGFR-1, VEGFR-
2, and VEGFR-3 and, through activating different cascades, exert their various 
biologic effects.VEGFR-2 represents the major mediator of VEGF-driven responses 
in endothelial cells responsible for most VEGF angiogenic activities. Neuropilins 
(NRP-1 and NRP-2) are known as co-receptors for VEGF. 
Other Proangiogenic Factors 
The platelet-derived growth factor (PDGF) family of molecules is structurally related 
to the VEGF family and has significant angiogenic properties invitro and in vivo.  
DRUGS THAT TARGET VEGF RECEPTORS 
[6] 
Vascular endothelial growth factor (VEGF) is a protein that helps tumors form new 
blood vessels to get nutrients. Drugs that stop VEGF from working can be used to 
treat some colon or rectal cancers. These include: 
 Bevacizumab (Avastin) 
 Ramucirumab (Cyramza) 
 Ziv-aflibercept (Zaltrap) 
 
These drugs are given as infusions into your vein (IV) every 2 or 3 weeks, typically 
along with chemotherapy. When combined with chemo, these drugs can often help 
patients with advanced colon or rectal cancers live longer. 
 
Structure of vascular endothelial growth factor receptor (VEGFR) inhibitors 
                               
 
                           1. Pazopanib                                                   2. Axitinib 
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                 3. Sunitib                                       4. Lapatinib(Tykerb)  
 POSSIBLE SIDE EFFECTS OF DRUGS THAT TARGET VEGF
[6] 
 Common side effects  
 High blood pressure, tiredness, bleeding, low white blood cell counts(with increased 
risk of infections), headaches, mouth sores, loss of appetite, and diarrhea. 
 Rare serious side effects  
 Blood clots, severe bleeding, holes forming in the colon (called perforations), heart 
problems, slow wound healing and allergic reaction during the infusion. 
 
 
CHEMISTRY AND PHARMACOLOGICAL ACTIVITIES OF 
PYRAZOLE AND PYRIDAZINE 
 
        Pyrazole refers to the class of simple aromatic ring organic compounds of the 
heterocyclic series characterized by a 5-membered ring structure composed of three 
carbon atoms and two nitrogen atoms in adjacent positions.Being so composed and 
having pharmacological effects on humans, they are classified as alkaloids, although 
they are rare in nature. In 1959, the first natural pyrazole, 1- pyrazolyl-alanine, was 
isolated from seeds of watermelons.
[13]
A systematic investigation of this class of 
heterocyclic lead revealed that pyrazole containing pharmacoactive agents play 
important role in medicinal chemistry. Pyrazoles are used for their anti-inflammatory, 
antioxidant, ACE inhibition, antitumour, antitubercular, antiviral, antidepressant, 
anticonvulsant, antifungal and anti-bacterial activities. 
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                                                                Pyrazole 
Literature survey revealed that various N-substituted pyrazoles have been 
implemented as antileukemic, antitumor, antiproliferative, anti-angiogenic, DNA 
interacting, proapoptotic, autophagy, and antitubulin agents. Moreover these 
compounds are capable to exert remarkable anti-cancer effects through inhibition of 
different types of enzymes, proteins and receptors which play critical role in cell 
division.
[14] 
                                                                                                            
Pyridazine is a compound that belong to the class of diazines. Pyridazines are 
heterocyclic compounds that contain two adjacent nitrogen atoms (1,2-diazine) in the 
ring structure. They show a wide range of pharmacological activities and are found in 
a lot of natural compounds having different biological activities. There are three types 
of diazines: pyridazine, pyrimidine and pyrazine. The pyridazine compounds possess 
various pharmacological activities such as antihypertensive, antidepressant, 
hepatoprotective, anti-HIV, antibacterial, antimicrobial, cardiotonic, vasodilation, 
5HT antagonist etc. In addition, Pyridazine derivatives has remarkable anti cancer 
activity against leukemia, non-small cell lung cancer, colon, central nervous system, 
melanoma, ovarian and breast cancer cell lines.
[1]
 
MOLECULAR MODELLING
 [15] 
Molecular modeling is a general term used to describe the use of computers to 
construct molecules and perform a variety of calculations on these molecules in order 
to predict the chemical characteristics and behaviour. Molecular modelling 
encompasses all theoretical methods and computational techniques used to model or 
mimic the behaviour of molecules.The benefit of molecular modelling is that it 
reduces the complexity of the system allowing many more particles (atoms) to be 
considered during simulations.  
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In the recent years the search of novel drugs has evolved from the process of 
trial and error into a sophisticated procedure including several computer based 
approaches. In structure based design, the structures of known target proteins are used 
to discover new compounds of therapeutic relevance.The approaches can be classified 
roughly into two categories: de novo design and docking.  
Figure 9: Protein and ligand docked complex 
 
MOLECULAR DOCKING
 [15]
 
In the field of molecular modeling, docking is a method which predicts the 
preferred orientation of one molecule to a second when bound to each other to form a 
stable complex. Knowledge of the preferred orientation in turn may be used to predict 
the strength of association or binding affinity between two molecules. The association 
between biologically relevant molecules such as proteins, nucleic acids, carbohydrates 
and lipids play a central role in signal transduction. Furthermore, the relative 
orientation of the two interacting partners may affect the type of signal produced. 
Therefore, docking is useful for predicting both the strength and type of signal 
produced.  
  
Docking is frequently used to predict the binding orientation of small molecule drug 
candidates to their protein targets in order to predict the affinity and activity of small 
molecules. Hence docking plays an important role in the rational design of drugs. 
During the process of molecular docking the ligand binds to the particular molecule of 
interest and they adjust their conformations to achieve an optimised conformation to 
achieve an overall ―best fit‖ and this kind of conformational adjustments resulting in 
the overall binding is referred to as ― induced fit‖. The aim of the molecular docking 
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is to achieve an optimised conformation for both the protein and ligand such that the 
free energy of the overall system is minimised.  
 
The application of computational methods to study the formation of intermolecular 
complexes is a subject of intensive research. Drug exerts its biological activity by 
binding to the pocket of receptor molecule (usually protein). In their binding 
conformations, the molecules exhibit geometric and chemical complementarily, both 
of which are essential for successful drug activity. Molecular docking helps in 
studying drug/ ligand or receptor/ protein interactions by identifying the suitable 
active sites in protein, obtaining the best geometry of ligand-receptor complex and 
calculating the energy of interaction for different ligands to design more effective 
ligands.  
 
The target or receptor is either experimentally known or theoretically generated 
through knowledge based protein modelling or homology modelling. The molecular 
docking tool has been developed to obtain a preferred geometry of interaction of 
ligand-receptor complexes having minimum interaction energy based on different 
scoring functions namely only electrostatics, sum of steric and 
electrostatic(parameters from MMFF force field) and dock score. This utility allows 
one to screen a set of compounds for lead optimisation.  
 
TOXICITY PREDICTION
[16] 
The investigation of ADMET properties of a compound is a crucial step in the drug 
development process which involves the absorption, distribution, metabolism, 
excretion and toxicity studies. The ADMET properties of a drug candidate have to be 
determined, before its proceeds into clinical trials. The usual toxicity studies were 
conducted in animal experiments are time-consuming and take animal lives. In silico 
toxicity predictions are a fast and inexpensive alternative to animal experiments. They 
rely on known toxicity data which is used to develop a model capable of predicting 
toxicities of new compounds.  
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PREDICTION OF RODENT ORAL TOXICITY
[17] 
PROTOX is a webserver for the prediction of oral toxicities of small molecules in 
rodents. 
The prediction of compound toxicities is an important part of the drug design 
development process. Computational toxicity estimations are not only faster than the 
determination of toxic doses in animals, but can also help to reduce the amount of 
animal experiments. PROTOX webserver is based on chemical similarities between 
compounds with known toxic effects and the presence of toxic fragments. 
ECOTOXICITY PREDICTION
[18] 
 
GUSAR software is used for Quantitative prediction of ecotoxicity for chemical 
compounds. The QSAR models were developed for the following endpoints: 96-hour 
fathead minnow 50% lethal concentration, 48-hour daphnia magna 50% lethal 
concentration, Tetrahymena pyriformis 50% growth inhibition concentration and 
Bioconcentration Factor. 
GUSAR software was developed to create QSAR/QSPR models on the basis of the 
appropriate training sets represented as SDfile contained data about chemical 
structures and endpoint in quantitative terms. 
ACUTE RAT TOXICITY PREDICTION
[18] 
In silico prediction of LD50 values for rats with four types of administration (oral, 
intravenous, intraperitoneal, subcutaneous, inhalation) by GUSAR software. The 
training sets were created on the basis of data from SYMYX MDL Toxicity Database. 
They include the information about ~10000 chemical structures with data on acute 
rat‘s toxicity represented on the LD50 values. 
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2. REVIEW OF LITERATURE 
1. Ibrahim M A et al.,
[19]
 studied the various pharmacological activities of 
pyridopyridazine derivatives[1] which includes anticancer, antimicrobial, 
analgesics,anti-histaminic,anti-asthmatics,anti-inflammatory,anti tuberculosis. 
These properties made them as an important scaffold for the development of 
new drugs. 
      
       
                                                      [1]          
                                         
2. Ewies F. Ewies et al.,
[20]
 synthesised some novel pyridazine derivatives[2] 
and evaluated for its antitumor activity.The invitro cytotoxicity activity was 
carried out against liver HEPG2 cancer cell lines in comparison to the known 
anticancer drugs: 5-Flurouracil (5-FU) and Doxorubicin (DOX) using SRB 
assay. The cytotoxic and growth inhibitory activity of the compound 3a (IC50: 
3.92 μg/mL) was very close to that of the 5-Flurouracil reference drug (IC50: 5 
μg/mL) against liver carcinoma cell line (HEPG2). 
                                             
                                                           [2] 
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3. Mohammad Asif 
[1]
 studied the anticancer potential of various 
pyridazines[3] and related compounds. Almost all compounds showed 
remarkable activity against leukemia, non-small cell lung cancer, colon, central 
nervous system, melanoma, ovarian  and breast cancer cell lines. 
                                            
                                                     [3] 
4. Naoki Miyamoto et al.,
[21] 
synthesised 2-acylamino-6-phenoxy-imidaz[1,2-
b]pyridazine derivatives. Among these, N-[5-({2-[(cyclopropyl carbonyl) 
amino]imidazo[1,2-b]pyridazine-6yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-
pyrazole-5-carboxamide(23a,TAK-593) [4] is a highly potent VEGFR2 
kinase(PDB Code: 3VO3) inhibitor with an IC50 value of 0.95Nm.The 
compound shows inhibition of platelet-derived growth factor receptor kinases 
as well as VEGF receptor kinases in kinase selectivity profiling. 
                             
                                                                   [4] 
 
5.Shigemitsu Matsumoto et al.,
[22]
 designed and synthesised a novel series of 
imidazo[1,2-b]pyridazine [5] and imidazo[1,2-a]pyridine derivatives as dual c-
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Met and VEGFR2 kinase(PDB code: 3VO3) inhibitors. Compound 26 
exhibited antitumour efficacy in vivo in MKN45 and COLO205 mouse 
xenograft models. 
                                    
                                                    [5] 
                                           
6.   I.G.Rathish et al.,
[23]
 synthesised and studied anticancer activity of some 
novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones[6]. Among 5 
derivatives synthesised ,2h has been selected as lead compound for developing 
new anticancer agents.  
 
                                      
                                                           [6] 
7. Naoki Miyamoto  et al.,
[24]
 designed  and synthesised  imidazo[1,2-
b]pyridazine derivatives having a benzamide unit  and evaluated for  its 
VEGFR2 kinase inhibition.Almost all the tested compounds revealed anti 
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tumour activity.In which, a strong inhibitory activity was showed by N-[3-
(imidazo[1,2-b]pyridazin-6-yloxy)phenyl]-3-(trifluoromethyl)benzamide[7]  
against VEGFR2 with an IC50 value of 7.1Nm.     
                                                
                                              [7] 
8. Mishra Pankaj et al.,
[25]
 synthesised and characterised some cinnoline 
derivatives and evaluated its activities like anti-hypertensive, antithrombotic, 
antihistaminic, antileukemic, CNS activity, anti tumor, antibacterial and anti 
secretory. Halogen substituted Cinnoline imidazole compounds[8] mainly 
Chloro substituted were showed potent antibacterial, anti-inflammatory and 
anti-fungal activity than other compounds.However methyl substituted 
compound also showed more potent antimicrobial activity and anti-
inflammatory activity.  
                                       
                                                          [8] 
9. Eman D. Awad et al.,
[26] 
synthesized series of 6-substituted-4-methyl-3-(4-
aryl piperazin-1-yl) cinnolines[9] and the antitumour, antibacterial, and 
antifungal activity of the newly synthesized compounds were evaluated.  
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                                                         [9] 
10. V. Kumar et al.,
[27] 
synthesised a new series of pyrido[2,3-c]pyridazine 
derivatives[10] and  screened for its antitumor activity. Amongst them few of 
the compounds have exhibited promising cytotoxicity along with good safety 
index  and could be of use in designing new anti-cancer agents.               
 
                                  
                                                        [10]                                                             
 
11. Lei Shi et al.,
[28]
 designed  and studied a series of  N-(2-phenyl-1H-
benzo[d]imidazol-5-yl)quinazolin-4-amine derivatives[11] as dual c-Met and 
VEGFR-2 inhibitors. Both c-Met and VEGFR-2 are important targets for the 
treatment of cancers. Among these compounds, 7j exhibited the most potent 
inhibitory activity against c-Met and VEGFR-2 with IC50 of 0.05 lM and 0.02 
lM, respectively. It also showed the highest anticancer activity against the 
tested cancer cell lines with IC50 of 1.5 lM against MCF-7 and 8.7 lM against 
Hep-G2. Docking simulation supported the initial pharmacophoric hypothesis 
and suggested a common mode of interaction at the ATP-binding site of c-Met 
and VEGFR-2, which demonstrates that as a potential agent for cancer therapy 
deserving further researching. 
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                                                    [11] 
12.  Huahui Zeng et al.,
[29]
 designed 3D-QSAR modeling and molecular 
docking study on 1,4-dihydroindeno[1,2-c]pyrazoles [12] as VEGFR-2 kinase 
inhibitor. By using  molecular docking method, binding of VEGFR-2(PDB 
ID:1Y6A)  with its inhibitors were studied. The satisfactory results were 
obtained suggest that these methods are reasonable for the prediction of new 
inhibitors and in future drug design. 
                                                   
                                                            [12] 
13. Mai. I. Shahin 
[30]
 designed and synthesised type-II VEGFR2 inhibitor 
based on quinoxaline[13] scaffold. The target compounds are biologically 
evaluated for their inhibitory activity against VEGFR2. 
                                     
                                                            [13]    
14.Vinod G. Ugale et al.,
[31]
 studied pharmacophore modeling  for a  series of 
quinoline derivatives[14] as VEGFR2 inhibitors. Docking studies were carried 
out  to analyse drug-receptor interactions and may prove helpful for further 
lead optimization and virtual screening. 
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                                            [14] 
15. Rachana R.Desai et al.,
[32]
 studied docking of  Vascular Endothelial 
Growth Factor with phytochemicals for  anti-angiogenesis. The molecular 
docking studies and post processing of docking results were carried out with 
natural compounds(phytochemicals) as ligand[15] against VEGF in 
comparison with Bevacizumab an anti-VEGF monoclonal antibody in order to 
avoid the side effects of older chemotherapy. 
                                                     
                                                               [15] 
 
16. Yuya Oguro et al.,
[33]
synthesized a series of pyrrolo[3,2-d]pyrimidine 
derivatives and evaluated their application as type-II inhibitors of vascular 
endothelial growth factor receptor 2 (VEGFR2, PDB code: IVR2) 
kinase.Among these derivatives, compound[16]  showed the strongest 
inhibition of VEGF-stimulated proliferation of human umbilical vein 
endothelial cells (HUVEC).The co-crystal structure of  [17] and VEGFR2 
revealed that[17]binds to the inactive form of VEGFR2. The studies reveals 
that [17] inhibited VEGFR2 kinase with slow dissociation kinetics and also 
inhibited PDGFR and Tie-2 kinases.  
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                                                                [16] 
                                                          
17. Mosaad Sayed Mohamed et al.,
 [34] 
synthesized a series of cyanopyridine 
derivatives, Schiff bases, urea and thiourea derivatives, amide derivatives, 
pyridopyrazolopyrimidine[17] and pyridopyrazolotriazine. Activities of eleven 
representative compounds were evaluated against A-549 (lung), HEPG2 (liver) 
and HCT-116 (colon) cancer cell lines. The findings revealed that some of the 
synthesized compounds showed remarkable anticancer activities. In addition to 
synthesis and biological activities, binding features of the potent compound 
with cyclin dependent kinase was performed using structure based modelling 
tools. 
 
[17] 
 
18. Qidong Tang et al.,
[35] 
synthesised two series of quinoline derivatives 
bearing the pyridine/pyrimidine scaffold[18] , and evaluated for their c-Met 
kinase inhibitory activity and antiproliferative activity against 5 cancer cell 
lines (HT-29, H460, MKN-45, A549, and U87MG) were evaluated in vitro. 
Structure activity relationship studies indicated that regulation of the electron 
density on the pyridine/pyrimidine ring to a proper degree was a key factor in 
improving the antitumor activity. 
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                                                              [18] 
 
19. Sai Li et al.,
[
 
36]
 designed and synthesised  a series of  bisquinoline 
derivatives connected by 4-oxy-3-fluoroaniline[19] moiety. In-vitro antitumour 
activities against a panel of five cancer cell lines (H460, HT-29,MKN-45, 
U87MG, and SMMC-7721) evaluated. An analysis of structureeactivity 
relationships indicated that an unsubstituted or a halogen-substituted phenyl 
ring on the 2-arylquinoline-4-carboxamide moiety was favourable for 
antitumour activity.             
                                      
                                                                 [19] 
 
20. Rajiv Kumar Tonk et al.,
[37] 
synthesized and characterized a series of 
pyrazolo[4, 3-c] cinnoline derivatives[20] and evaluated for anti-inflammatory 
and anti-bacterial activity. Test compounds that exhibited good anti-
inflammatory activity were further screened for their ulcerogenic and lipid 
peroxidation activity. Compounds 4d and 4l showed promising anti-
inflammatory activity with reduced ulcerogenic and lipid peroxidation activity 
when compared to naproxen. Docking results of these two compounds with 
COX-2 (PDB ID: 1CX2) also exhibited a strong binding profile. Among the  
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test derivatives, displayed significant antibacterial property against gram-
negative (Escherichia coli and Pseudomonas aeruginosa) and gram-positive 
(Staphylococcus aureus) bacteria. However, emerged as the best dual anti-
inflammatory antibacterial agent in the present study. 
                                                     
                                                            [20] 
 
21. Ghaneya Sayed Hassan et al.,
[38]
synthesized new series  of pyrazolo [3,4-
d]and pyrazole hydrazones[21] and evaluated for their antiproliferative activity 
against human breast adenocarcinoma MCF-7 cell line. Most of the tested 
compounds exploited potent to moderate growth inhibitory activity to the 
reference drug cisplatin. The antitumor activity of the new compounds was 
accompanied by significant increase in the activity of superoxide dismutase 
with concomitant decrease in the activities of catalase and glutathione 
peroxidase and reduced glutathione level. Accordingly, the overproduction of 
hydrogen peroxide, nitric oxide and other free radicals allowed reactive oxygen 
species (ROS)-mediated tumor cells death, as monitored by reduction in the 
synthesis of protein and nucleic acids. 
                                            
                                                              [21] 
22. Magdy I. El-zahar et al.,
 [39] 
synthesized a  new series of (benzofuran-2-
yl)-1-phenyl-1H-pyrazol-4-yl) pyrimidine derivatives[22]. Some docking 
Review of literature 
 
Department Of Pharmacology, KMCH College Of Pharmacy 43 
 
studies of the newly prepared compounds as thymidylate synthase inhibitors 
have been done. The cytotoxic activity of some of the prepared compounds as a 
representative examples was evaluated against HEPG2 (human liver carcinoma 
cell line) in comparison with 5-fluorouracil (5-Fu). 
                                  
                                                             [22] 
23. David A. Scott et al.,
[40]
 3-Amido-4-anilinocinnolines[23] have been 
identified as potent and highly selective inhibitors of CSF-1R. The synthesis 
and SAR of these compounds is reported, along with some physical property, 
pharmacokinetic and kinase selectivity data. 
                                       
                                                                   [23] 
 
24.  Diaa A. Ibrahim et al.,
[41]
designed and synthesized novel derivatives of 2, 
4,5,6-tetrasubstituted pyrimidine cyclin-dependent kinase[24] (CDK2) 
inhibitors. A library of proposed pyrimidine derivatives was built and by using 
pharmacophore and docking techniques selections were made. The newly 
synthesized compounds showed potent and selective CDK2 inhibitory activities 
and inhibited in-vitro cellular proliferation in cultured human tumour cells.  
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                                                        [24] 
 
25. Marta Szumilak et al.,
[42]
 synthesised  new polyamine derivatives 
containing dimeric quinoline, cinnoline[25] and phthalimide moieties. The new 
compounds were obtained according to known procedures. Their biological 
activity was assessed in vitro in a highly aggressive melanoma cell line A375. 
Polyamine diimides containing phthalimide moieties demonstrated no 
inhibitory activities against melanoma cells. Quinoline diamides were more 
efficient than cinnoline ones. Mainly cytostatic activity exerted as altered cell 
cycle profiles was observed at the concentrations causing about 50% reduction 
of adherent cell proliferation. Based on their structure as well as their 
biological activity, we assume that some of the newly synthesized compounds 
may act as DNA bisintercalators. This study might be useful for further 
designing and developing anticancer drugs with potent activities. 
 
 
[25] 
 
26. T.V.Yuvaraj et al.,
[43]
synthesised a series of 3’-methyl-6-sulphamido-
1’substituted-pyrazolo [4,3-c] cinnoline derivatives[26]. The compounds were 
characterized by analytical techniques like TLC, UV, IR, NMR Spectral 
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studies. The compounds were screened for antimicrobial activity against 
bacterial organisms like Escherichia coli, Klebsiella aurogeniosea, 
Micrococcus luteus, Bacillus cereus and fungal organism like Candida 
albicans. 
                                               
                                                            [26] 
 
27. Mourad Chioua et al.,
[44]
synthesised and biologically evaluated a number 
of differently substituted 3,6-diamino-1H-pyrazolo[3,4-b]pyridine 
derivatives[27]. From the inhibition results on a selection of disease-relevant 
protein kinases they observed that 3,6-diamino- 4-phenyl-1H-pyrazolo[3,4-
b]pyridine-5-carbonitrile constitutes a potential new and simple lead compound 
in the search of drugs for the treatment of Alzheimer’s disease. 
                                             
                                                            [27] 
 
28. Kirk L. Stevens et al.,
[45]
 synthesized and identified a novel series of 
pyrazolo [1,5-b] pyridazines[28] as cyclin dependant kinase inhibitors 
potentially useful for the treatment of solid tumours. Modification of the hinge-
binding amine or the C (2) and C (6) substitutions on the pyrazolopyridazine 
core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity 
against VEGFR-2 and GSK3β. 
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                                                            [28] 
29.Jamal M. Arif et al.,
[46]
screened newly synthesized antiviral 
aminopyrazoloquinoline derivatives[29] for cytotoxic potential in human 
normal and breast cancer cell lines using apoptosis as biomarker. These 
derivatives and the well known antiviral drug, acyclovir, were incubated with 
the normal (MCF-10A, MCF-12A) and cancer (MCF-7, MDA-MB-231) cell 
lines. Both the parent compounds and their sugar derivatives were found to be 
differentially cytotoxic in various cell lines. Their study suggested that the 
newly synthesized antiviral compounds have an associated risk of being 
cytotoxic compared to the acyclovir. 
 
 
[29] 
 
 
30. Thierry O. Fischmann et al.,
[47] 
discovered CDK2 inhibitors containing 
the related bicyclic heterocycles imidazopyrazines and 
pyrazolopyrimidines[30] through high-throughput screening. Crystal structures 
of inhibitors with these bicyclic cores and two more related ones show that all 
but one have a common binding mode featuring two hydrogen bonds (H-
bonds) to the backbone of the kinase hinge region. Even though ab initio 
computations indicated that the imidazopyrazine core would bind more tightly 
to the hinge, pyrazolopyrimidines gain an advantage in potency through 
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participation of N4 in a H-bond network involving two catalytic residues and 
bridging water molecules. Further insight into inhibitor/CDK2 interactions was 
gained from analysis of additional crystal structures. 
                                               
                                                       [30] 
 
31. Miguel F. Brana et al.,
[48]
identified Pyrazolopyridazine[31] in a high-
throughput screening carried out by BASF Bioresearch Corp. as a potent 
inhibitor of CDK1/cyclin B and shown to have selectivity for the CDK family. 
Analogues of the lead compound were synthesized and their antitumour 
activities have been tested. A molecular model of the complex between the lead 
compound and the CDK2 ATP binding site has been built using a combination 
of conformational search and automated docking techniques.  
 
         
                                               
 
                                               
                                                             [31]                                            
32.Wieslawa Lewgowd et al.,
[49]
 synthesised pyrimido[5,4-c]cinnoline [32] 
and pyrimido[5,4-c]quinoline derivatives and determined its cytotoxicity on the 
two human leukemia cell lines, the promyelocytic HL-60 and the 
lymphoblastic NALM-6.The continous exposed cell viability was found out by 
the tryptan-blue exclusion assay. IC50 value suggested that the HL-60 leukemia 
cells are more resistant to toxic action of tested compounds.All compounds 
exerted moderate cytotoxic activity.  
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                                                     [32] 
33.   Younong Yu et al.,
 [50]
 synthesised several substituted dibenzo[c,h] 
cinnolines [33] and evaluated for their potential to target topoisomerase I and 
for their relative cytotoxicity activity as in anticancer agents.With regards to 
topoisomerase I-targeting activity and cytotoxicity 2,3-Dimethoxy-8,9-
methylenedioxybenzo[i]phenanthridine was one of the more potent 
benzo[i]phenanthridine derivative.These results indicate that substituted 
dibenzo[c,h]cinnolines can exhibit potent topoisomerase I targeting activity and 
are capable of overcoming the multi-drug resistance associated with this efflux 
transporter.  
                                              
                                                         [33] 
 
34.Gabriele Murineddu et al.,
[51]
 synthesised and evaluated in vitro 
cytotoxicity activity of Pyrrole[2,3-d]pyridazine-4-one derivative[34] against 
60 human tumor cell lines derived from nine cancer cell types. Among them, 
the most potent compound 3 showed significant cell line cytotoxicity, 
particularly against the renal cancer subpanel and displayed significant potency 
against MOLT-4, SR (leukemia), NCI-H460 (non-small cell lung), HCT-116 
(colon), and SF-295 (CNS) cancer cells, respectively. 
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                                                               [34] 
35. Neetinkumar D. Reddy et al.,
[52]
 evaluated invitro and invivo studies of  
novel cinnamyl sulphonamide hydroxamate derivative[35] against colon 
adenocarcinoma.1,2-Dimethyl hydrazine(DMH) was used to produce 
experimental colon adenocarcinoma in Wistar rats. 5-FU and NMJ-2(100mg/kg 
p.o. and 10mg/kg i.p. once daily for 21 days, respectively) were administered 
to the respective groups.Both therapy  showed significant reduced ACFs, 
adenocarcinoma count, TNF-a,IL-6 and nitrate in colonic tissue.The results 
indicates that NMJ-2 has potent anti-cancer activity through HDAC enzyme 
inhibition.Thus, the effectiveness of these molecules were evaluated by whole 
cell HDAC assay in HCT 116 cell line. 
                                                 
                                                 [35] 
36. H.M.Kuznietsova et al.,
[53]
 evaluated the comparative effects of cytostatic 
compound dihydropyrrol derivative(D1)[36] and 5-Fluorouracil(5-FU) on the 
normal colonic mucosa of tumor-bearing rats and also correlated the 
proliferation of normal colonic mucosa and tumor growth parameters.DMH 
carcinogenic model was used.D1 manifests the same antitumor activity with 
less toxicity compared to 5-FU that allows it to meaned as an anticancer agent. 
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                                                            [36] 
37. Wasfi Asfour et al.,
[54]
 studied the chemopreventive efficacy of 
Thymoquinone(TQ)[37] against DMH induced colon carcinogenesis in the rat 
model.A two-phase study was used to evaluate its potential impact on tumor 
progression and invasion in vivo.TQ treatment demonstrated a negative impact 
on vascular endothelial growth factor(VEGF) production in tumor-bearing rats 
which results in suppressed cellular proliferation.The results could provide an 
effective approach in the primary prevention of colon cancer in humans in the 
next future. 
                                                  
                                                             [37] 
38. Aranya Manosroi et al.,
[55]
 evaluated the invitro anti-cancer activities of 
Job’s tears(Coix lachrymal-jobi Linn.) extracts on human colon 
adenocarcinoma cell line(HT-29) by sulforhodamine B (SRB)assay.  
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3. AIM AND OBJECTIVES 
 
                    Cancer is a group of diseases characterised by a high proliferative index 
and the spread of aberrant cells from their site of origin. A combination of surgery and 
radiotherapy with chemotherapy is the clinical therapeutic treatment for cancer. 
Recent chemotherapy consists of cytotoxic agents and anti-hormonal drugs, which 
reduce the proliferation of the tumors. The use of anticancer drugs is complicated by 
systemic toxicity, generally in the bone marrow, hair and gastrointestinal tract, and 
also by development of resistance. As a result, the search for new chemical structures 
with broader therapeutic windows and acceptable resistance profiles is being 
vigorously pursued. Discovering new anticancer agents requires continued 
commitment to the demanding tasks remains critically important.
 [1]
 
                    The first step for the discovery of anticancer drugs should be focused on 
the use of methodologies which can provide a rationalization of the serendipitous 
process of organic synthesis in Medicinal Chemistry and Drug Design. In this sense, 
the modern science has the strong support of novel paradigms which have been 
essential for the discovery of new chemotherapies for dissimilar diseases: Molecular 
Docking and Computer Aided Drug Design (CADD).
[15]
  
               More recently, pharmaceutical attention has been focussed on the proteins 
that drive and control cell cycle progression.The significance of these potential drug 
targets is clearly evidenced by the high incidence of alterations in the genes that code 
for these proteins in tumours. One such protein is Vascular endothelial growth 
factor receptor2  which are proved to be viable target for development of effective 
and safe anti- cancer drugs. 
              Angiogenesis is the genesis of new blood vessels which involves the 
migration ,growth and differentiation of endothelial cells, which line inside the wall of 
the blood vessels and  is controlled by chemical signals in the body which stimulates 
the repair and formation of blood vessels. The process of angiogenesis has an 
important role in the growth and metastasis  of cancer. A blood supply is essential for 
cancer cells to grow beyond a few millimetres in size and also stimulate the nearby 
normal cells to form angiogenesis signaling molecules.Without  a blood supply, 
cancer cells cannot grow beyond a limit , hence the scientists were trying to find 
solutions to block tumor angiogenesis. Angiogenic inhibitors were studied and 
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identified with the idea that these molecules will prevent or slow down the cancer 
growth.
[56] 
                  There are several regulators of angiogenesis, such as vascular endothelial 
growth factor (VEGF), platelet-derived growth factor(PDGF),basic fibroblast growth 
factor(bFGF), and angiopoietin. The VEGF signaling pathway through the tyrosine 
kinases receptor VEGFR-1 and VEGFR-2 are critical regulators of angiogenesis.The 
VEGF receptor protein-tyrosine kinases consist of an extracellular component with 7 
immunoglobulin-like domains, a juxtamembrane segment,a single transmembrane 
segment,an intracellular protein-tyrosine kinase domain that has an insert of nearly 70 
amino acid residues, and a carboxyterminal domainal tail.A conformational change 
will occurs after the binding of VEGF  to VEGFR2 and will leads to receptor 
dimerization ,which is followed by the autophosphorylation of tyrosine residues 
present in the intracellular kinase domain.Vascular endothelial growth factor (VEGF) 
signaling through VEGF receptor-2 (VEGFR2) has been shown to play a major role 
in the regulation of tumour angiogenesis (fig. 10). Therefore, inhibition of VEGFR-2 
has become an attractive target for the development of novel anticancer agents.
[24] 
 
Figure
 
10: represents VEGF/VEGFR Role in Tumor Angiogenesis 
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Figure 11: Anticancer Drugs Targeting VEGF Pathway 
 
Many anticancer drugs that are available in the market and some under clinical trials 
have structural similarity with nucleotides and acts as competitive inhibitors of  
nucleotides that binds with tyrosine kinases receptor like VEGFR and other tyrosine 
kinases and thus retards tumour growth.
[56]  
Competitive Inhibitors Of  Nucleotides
 
                       
The search for small-molecule inhibitors of VEGFR2s has already led to the 
discovery of several classes of compounds with high structural diversity. Most 
VEGFR2 inhibitors share common properties and they act by competing with ATP for 
binding in the kinase ATP binding site and thus retards tumour growth.
[56]
 
                                                                               Aim and Objectives 
 
Department Of Pharmacology, KMCH College Of Pharmacy 54 
  
 
Structure: (A)- ATP, (B)-Anti cancer drugs acting as competitive inhibitors of  
ATP by binding with VEGFR. 
 
 
 
Drugs that inhibit VEGF from working can be used to treat some colon or rectal 
cancers. These include: 
 Bevacizumab (Avastin) 
 Ramucirumab (Cyramza) 
 Ziv-aflibercept (Zaltrap) 
 sorafenib, sunitinib, pazopanib, Lapatinib and axitinib are the drugs being 
evaluated in clinical trials. 
 
Pyrazolo pyridazine have structural similarity with many purine nucleotides 
[pyrimidine and imidazole]  like ATP which are helpful in the cell growth and thus 
Pyrazolo pyridazine can also compete with nucleotides for binding with the receptor 
proteins and can retard the growth of abnormal cells. 
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                                     Capecitabine 
 
Pyrazole is a versatile nucleus with various biological activities, and many anti 
cancer drugs have the pyrazole moiety.
[14] 
 
                         
              1. Pazopanib                                    2. Axitinib 
 
                                      
A huge number of pyridazine derivatives attract significant attention 
due to the recent reports of its antitumor activity. Some of the pyridazinone 
derivatives bearing different moieties were exhibited excellent anticancer activity 
toward human cancer cell lines. They showed remarkable activity against leukemia, 
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non-small cell lung cancer, colon, central nervous system, melanoma, ovarian and 
breast cancer cell lines. There are a variety of mechanisms of their antitumor action, 
including carbonic anhydrase inhibition, disruption of microtubule assembly, cell 
cycle arrest in the G1 phase, functional suppression of the transcriptional activator 
and angiogenesis inhibition. Currently, some of these derivatives are being evaluated 
in clinical trials, with much optimism that may lead to novel anticancer drugs, which 
is devoid of the side effects of the recently available anticancer drugs.
[1]
 
 
 Pyrazolo pyridazine is isosteric with many nucleosides which are acting as anti 
tumour drugs which are also available in the market.  
            
                                                                                                                            
Capecitabine 
 
 Moreover, the pyrazole and pyridazine nucleus have a broad spectrum of 
biological activities such as anti-inflammatory, antioxidant, ACE inhibition, 
antitumour, antitubercular, antiviral, antidepressant, anticonvulsant, antifungal and 
antibacterial activities.
 
  The therapeutic importances of this nucleus as antitumour agents have prompted 
us to select this nucleus.
 
                                                                      
 
 The emphasis has been put on the molecular modulation specifically 
modifying different substituents and its positions in the aromatic system.
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 Therefore efforts were taken to design and develop Pyrazolo benzpyridazine 
derivatives whose basic nucleus will be a structural analog with nucleosides 
involved in cell cycle and can compete with it and to study its effect against cancer 
cells in order to get  potent anti-tumour agents.  
 Hence the aim and objective of study was to design the lead molecules based 
on literature and to study its binding energies and docking interactions with 
specific protein VEGFR family and to synthesis Pyrazolo benzpyridazine 
derivatives and its in vitro and in vivo screening for anticancer activity.  
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4. PLAN OF WORK 
                                           Target selection 
 
                                              Selection and design of Ligand 
 
                  Lead optimisation by Molinspiration Software 
 
                        Molecular Docking studies by Glide 10.1 Software 
 
             Synthesis, characterisation and spectral analysis. 
  
In-vitro antioxidant study of synthesised compounds by DPPH 
and ABTS radical scavenging assay. 
 
          
In vitro cell line (HT 29) assay by MTT method. 
 
 
 Acute toxicity studies according to OECD Guideline 423. 
 
 
                          In vivo animal studies. 
1. Estimation of Tumerogenesis 
2. Estimation of Haematological Parameters like 
RBC,WBC and Haemoglobin 
3. Estimation of Serum Biochemical Parameters like 
SGOT, SGPT, ALP, Creatinine, total protein. 
4. In vivo antioxidant Study includes catalase, SOD, GPx, 
GSH, Lipid peroxidation. 
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5. Estimation of Enzymes involved in Citric acid 
cycle[TCA]  
6. Histopathological analysis 
7. Immunohistochemical reactivity 
 
    
         Statistical analysis 
        
                            Results and discussion 
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5. METHODOLOGY 
 
5.1 TARGET SELECTION 
               The accumulation of genetic and biological information from solid tumours 
is providing additional targets that have the potential of yielding drugs with broad 
activity and less toxicity than current therapies. Because of genomic stability, the 
endothelial cells are found to be an ultimate target for therapies focussed against 
cancer cells.
[45] 
                            Angiogenesis is the process in which angiogenic endothelial cells 
will undergo a series of events that includes the secretion of metallo-proteases and 
other matrix-degrading enzymes, cell migration into the newly created space, 
endothelial cell division and proliferation, including new capillary blood vessel 
formation from pre-existing vasculature. There are several regulators of angiogenesis, 
such as vascular endothelial growth factor (VEGF), platelet-derived growth 
factor(PDGF),basic fibroblast growth factor(bFGF), and angiopoietin. The VEGF 
signaling pathway through the tyrosine kinases receptor VEGFR-1 and VEGFR-2 are 
critical regulators of angiogenesis. The VEGF receptor protein-tyrosine kinases 
consist of an extracellular component with 7 immunoglobulin-like domains, a 
juxtamembrane segment, a single transmembrane segment, an intracellular protein-
tyrosine kinase domain that has an insert of nearly 70 amino acid residues, and a 
carboxyterminal domainal tail. The reaction catalysed by these enzymes include: 
 
            MgATP
1-  
  +  protein-OH                          Protein-OPO3
2-
 + MgADP+ H
+ 
          Where –OH is a tyrosyl hydroxyl group. 
 
          A conformational change will occurs after the binding of VEGF  to VEGFR2 
and will leads to receptor dimerization ,which is followed by the autophosphorylation 
of tyrosine residues present in the intracellular kinase domain(fig.12).
[57]
 The 
VEGF/VEGFR2 signaling pathway stimulates the cancer development by supplying 
oxygen and nutrients for the growing tumour cells, hence it plays an important role in 
tumour angiogenesis. VEGF is overexpressed in various classes of human tumours 
and its levels can be correlated with poor prognosis and clinical stage in patients with 
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solid tumours . Therefore, VEGF/VEGFR2 signaling can de regarded as an potential 
target in the treatment of cancer. In fact, several VEGFR2 inhibitors including 
sorafenib, sunitinib, pazopanib and axitinib are being evaluated in clinical trials. 
VEGFR2 inhibitors have garnered attention recently for their potential as anticancer 
therapeutics.VEGFR2 was selected as the target due to the potential as good anti-
cancer target.
[24] 
Figure 12: Biochemical conversion 
 
 
 
         Various protein structures of VEGFR2 in complex with different ligands are 
available in RCBS protein data bank, out of which 3VO3 has been selected because of 
the structural similarities of the ligand-N-[3-({2-[(cyclopropylcarbonyl) amino] 
imidazo[1,2-b]pyridazin-6-yl}oxy)phenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide 
in complex with 3VO3 and the designed molecules and is shown in fig.13.
[21] 
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Figure 13: 3VO3 protein in complex with ligand 
 
 
 
5.2 IN SILICO STUDIES 
     5.2.1 DRUG DESIGN 
 Lead molecule designed – Among several classes of potential VEGFR2 inhibitors, 
focus was made on Pyrazolo benzpyridazine derivatives due to its structural 
similarity with the natural ligand ATP and with structures of many known 
biologically active VEGFR2 inhibitors. Hence various Pyrazolo benzpyridazine 
were designed and emphasis was given on the molecular modulation specifically 
modifying different substituents and its positions in the aromatic system. 
 
Pyrazolo benzpyridazine 
 
5.2.2 LEAD OPTIMISATION
[58] 
Lead optimization was done through Molinspiration server for the purpose of 
calculation of logP. The structure drawn in was subjected to calculate the drug 
likeness score. Molinspiration Property Calculator which allows easy interactive 
calculation of molecular properties, as well as generation of data tables which may be 
used for structure-activity QSAR studies. 
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5.2.3  PREDICTION OF ACUTE TOXICITY[17] 
Acute toxicity testing involves an assessment of the general toxic effects of a 
substance that result either from a single exposure or from multiple exposures in a 
short period of time (usually less than 24 hours) and these adverse effects should 
occur within 14 days of the administration of the substance . 
Many acute toxicity studies have been conducted solely for the purpose of 
determining the LD50 in mg/kg body weight. The LD50 is the median lethal dose 
meaning the dose at which 50% of test subjects die upon exposure to a compound.     
Figure 14: In silico toxicity prediction 
 
 
 

 PROTOX is a web server for the prediction of oral toxicities of small 
molecules in rodents, an important part of the drug design development 
process. 

 Computational toxicity estimations are not only faster than the determination 
of toxic doses in animals, but can also help to reduce the amount of animal 
experiments.  
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
 PROTOX is based on chemical similarities between compounds with known 
toxic effects and the presence of toxic fragments.
[17]
 

 GUSAR software was developed to create QSAR/QSPR models on the basis 
of the appropriate training sets represented as SD file contained data about 
chemical structures and endpoint in quantitative terms.
[18]
 
5.2.4 DOCKING STUDIES 
      Glide(grid-based ligand docking with energetics) has been designed to perform as 
close to an exhaustive search of the positional, orientational, and conformational 
space available to the ligand as is feasible while retaining sufficient computational 
speed to screen large libraries.Glide uses a series of hierarchical filters to search for 
possible locations of the ligand in the active-site region of the receptor. The shape and 
properties of the receptor are represented on a grid by different sets of fields that 
provide progressively more accurate scoring of the ligand pose. Docking studies of 
designed compounds were carried out using GLIDE (Grid-based Ligand Docking 
with Energetics) module version 10.1, Schrodinger, LLC, New York, NY, 2015. The 
software package running on multi-processor Linux PC. GLIDE has previously been 
validated and applied successfully to predict the binding orientation of many ligands. 
5.2.4.1 DOCKING METHODOLOGY 
The steps involved in docking are as follows: 
 Ligand Preparation: The 2D structures of the designed molecules were 
constructed using Glide 2D sketcher and then it was created in 3D structure 
format. The LigPrep a utility in Schrodinger software suite that combines tools 
for generating 3D structures. 
 Preparation of protein: The X-ray crystal structures of the proteins 3VO3 
were obtained from the RCSB protein data bank (http://www.rcsb.org/pdb). 
After selection, the 3-dimensional structures of the protein it was analysed for 
potential binding pockets and then prepared by docking software Schrödinger-
Maestro 10.1. Usually the PDB structure consists of metal ions, cofactors, can 
contain waters and has no information on bond orders, formal atomic charges 
and misaligned terminal amide groups Ionization and tautomeric states. In 
order to acquire accurate energy evaluation the bond orders and ionization 
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states to be properly assigned, side chains to be reoriented and steric clashes to 
be relieved as Glide calculations are based on all-atom force field.  The 
missing side-chain atoms were added manually and the proteins were 
preprocessed separately by deleting the substrate cofactor as well as the 
crystallographically observed water molecules (water without H bonds), 
correcting the mistakes in PDB file, optimizing hydrogen bonds. After 
assigning formal charge with bond orders and protonation state finally energy 
minimization was done. 
 Receptor grid generation: Receptor grid generation requires a prepared 
structure: an all atom structure with appropriate bond order and formal 
charges. Glide searches for favourable interaction between one or more ligand 
molecules and a receptor molecule, usually a protein. The shape and properties 
of the receptor are represented on a grid by several different sets of field that 
provide progressively more accurate scoring of the ligand poses. The option in 
each tab of the Receptor Grid Generation panel allow defining the receptor 
structure  by excluding any co-crystallized ligand that may be present, 
determine the position and size of the active site as it will be represented by 
receptor grid, and set up Glide constraints. A grid area was generated around 
the binding site of the receptor. 
 Ligand docking: This is carried out using GLIDE DOCK. Glide searches for 
favourable interaction between one or more ligand molecule and a receptor 
molecule, usually a protein. Each ligand acts a single molecule, while the 
receptor may include more than one molecule, e.g., a protein and a cofactor. 
Glide a run in rigid or flexible docking mode; the latter automatically 
generated conformation for each input ligand. The combination of position 
and orientation of a ligand relative to the receptor, along with it conformation 
in flexible docking, is referred to as a ligand poses. The ligand poses that 
Glide generate pass through a series of hierarchical filter that evaluate the 
ligand to the defined active site, and examine the complimentarily of ligand-
receptor interaction using a grid-based method patterned after the empirical 
ChemScore function. Poses that passed the initial screen entered the final stage 
of the algorithm, which involve evaluation and minimization of a grid 
approximation to the OPLS-2005 non bonded ligand-receptor interaction 
energy. Final scoring is then carried out on the energy-minimized poses. 
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 Glide Extra-Precision Mode (XP) – The extra-precision (XP) mode of Glide 
combines a powerful sampling protocol with the use of a custom scoring 
function designed to identify ligand poses that would be expe8cted to have 
unfavourable energies, based on well- known principles of physical chemistry. 
The presumption is that only active compounds will have available poses that 
avoid theses penalties and also receive favourable scores for appropriate 
hydrophobic contact between the protein and the ligand, hydrogen-bonding 
interactions, and so on. The chief purposes of the XP method are to weed out 
false positives and to provide a better correlation between good poses and 
good scores. Extra-precision mode is a refinement tool designed for use only 
on good ligand poses. Finally, the minimized poses are re-scored using 
Schrodinger’s proprietary Glide Scores coring function. Glide Score is based 
on Chem Score, but includes a steric-clash term and adds buried polar terms 
devised by Schrodinger to penalize electrostatic mismatches: 
 
 
 
          Where, vdW: - Van der Waal energy; Coul: - Coulomb energy; Lipo: - 
Lipophilic contact term, H Bond: - Hydrogen-bonding term,Metal: - Metal-
binding term, BuryP: - Penalty for buried polar groups, Rot B: - Penalty for 
freezing rotatable bonds, Site: - Polar interactions at the active site; and the 
coefficients of vdW and Coul are: - a = 0.065, b = 0.1 
 
5.2.4.2 DOCKING PROCEDURE 
The computational modelling studies relied upon the GLIDE (Grid-based Ligand 
Docking from Energetics) program (Glide, version 10.1, Schrodinger, LLC New 
York, 2015) for the docking simulations.  These simulations were performed using the 
X-ray crystal structure of the human VEGFR2 (PDB ID: 3VO3). All the water 
molecules in the crystal structure were deleted, bond orders were assigned, hydrogens 
were added and the protein was then further refined for the docking studies by 
processing it using Schrodinger’s Protein preparation wizard.  This procedure 
minimizes the protein to 0.30 Å RMSD using OPLS-2005 force field. Ligands were 
Glide Score = 0.065*vdW + 0.130*Coul + Lipo + Hbond + Metal + BuryP + RotB +Site  
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prepared using build panel in maestro. Further the ligands were prepared for docking 
using LigPrep tool and were energy minimized using MMFF Force Field. Glide Grid 
generation panel has been used to generate receptor grid for docking. Default SP 
(Standard Precision) docking protocol was used to dock the library ligands. 
Molecular docking studies were performed using the GLIDE program (Masetro 
version 10.1, Schrodinger, LLC, New York, 2015) to understand the interaction of 
ligands with 3VO3. The Maestro user interface (version 10.1, Schrodinger, LLC, New 
York, 2015) was used to set up and execute the docking protocol and also for analysis 
of the docking results. Validation of docking protocol was done by redocking. Human 
VEGFR2 (PDB ID: 3VO3 protein) was selected for docking studies and was prepared 
for docking through protein preparation wizard, energy minimization has been carried 
out using OPLS2001 force field. Structures of the ligands were sketched using built 
panel on maestro and prepared for docking through Ligprep module (energy 
minimized using MMFF force field). GLIDE grid generation wizard has been used to 
define the docking space. 
5.3 EXPERIMENTAL PROCEDURES 
5.3.1 SYNTHESIS OF PYRAZOLO BENZPYRIDAZINE DERIVATIVES
12 
 
STEP1: Synthesis of Ethyl 3 –oxo-2-(2-substituted  
phenylhydrazinylidene)butanoate: 
Various substituted anilines (0.39mol) were dissolved in a mixture of concentrated 
Hydrochloric acid (15ml) and water (15ml) and cooled to 0-5°C in ice bath, then it 
was added to a cold saturated solution of sodium nitrite (0.58mol) with constant 
stirring. The diazonium salt thus formed was filtered into a cooled solution of ethyl 
acetoacetate (0.39mol) in ethanol and sodium acetate in water (to make it alkaline). 
The solid was collected and recrystallized from methanol.  
 
STEP2: Synthesis of 3-Acetylbenz pyridazine-4(1H)-one derivatives: 
 To Ethyl 3 –oxo-2-(2-phenylhydrazinylidene)butanoate(0.01mol) was added 
anhydrous Aluminium chloride (0.02 mol). Chlorobenzene (30ml) was added in order 
to dissolve the solids and the mixture was then refluxed for 1hr.the complex formed 
was decomposed with concentrated hydrochloric acid(30 mL) and diluted with cold 
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water.The product was filtered, washed with water, dried and recrystallized from 
methanol.  
 
STEP3: Synthesis of Pyrazolo benzpyridazine derivatives: 
A mixture of Ethyl 3 –oxo-2-(2-phenylhydrazinylidene)butanoate(0.005mol) and 
hydrazine hydrate/phenyl hydrazine (0.02mol) in ethanol was refluxed for 3 hrs. The 
product formed was collected and recrystallized from ethanol. Melting point and 
percentage yield of the above compound are determined.The scheme of synthesis is 
given in scheme. 
 
SCHEME OF SYNTHESIS OF PYRAZOLO BENZPYRIDAZINE 
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Table 2: Various substitutions for the synthesised compound 
COMPOUND  
CODE 
Substitution Position 
R R1 
Pz-1 
 
Cl H 
Pz-2 
 
Cl C6H5 
Pz-3 
 
F C6H5 
Pz-4 
 
NO2 H 
Pz-5 SO2NH2 
 
H 
Pz-6 SO2NH2 
 
C6H5 
 
5.3.2 PHYSICOCHEMICAL STUDIES AND CHARACTERIZATION OF 
SYNTHESIZED COMPOUNDS 
5.3.2.1 Melting point analysis: 
The melting point of the compounds were determined in one end fused capillary tubes 
on a THERMONIC MODEL-C-LMP-1,(Campbell melting point) apparatus was used to 
evaluate the purity of the synthesized compounds and were uncorrected. 
 
5.3.2.2 Thin layer chromatography (TLC): 
All the reactions were monitored using TLC. Purity of the synthesized compounds 
were assessed by a single spot in thin layer chromatography. The spot were visualised 
using Iodine chamber. The mobile phase used was chloroform: methanol - 0.2: 9.8. 
 Determination of Rf value is an important technique to identify the formation of 
synthesized compounds and to determine the purity of the compound. Rf value is the 
characteristic for each of the compound. 
                  Rf            =                Distance travelled by solute 
                                                   Distance travelled by solvent 
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5.3.3 SPECTRAL STUDIES: 
The structures of the compounds were characterised by Infrared Spectroscopy, Proton 
and 
13
C Nuclear Magnetic Resonance and Mass Spectroscopy analysis. 
 5.3.3.1 Infrared spectral analysis (IR): 
The infrared spectral study was done on JASCO FTIR 4100 using KBr disc.The 
spectral data is expressed in wave numbers (cm
-1
). 
 
5.3.3.2 Nuclear Magnetic Resonance spectral analysis (
1
H NMR & 
13
C NMR) 
The NMR spectra of the synthesized compounds were recorded by Bruker Fourier, 
Transform-NMR using TMS (Tetramethylsilane) as internal standard. The PMR 
(Proton Magnetic Resonance) and Carbon-13 Magnetic Resonancespectroscopic 
values were measured in δ ppm in DMSO-d6. 
5.3.3.3 Mass Spectral analysis: 
The mass spectra of newly synthesized compounds were recorded on Shimadzu 
LCMS-2010 EV instrument. The mass of the compounds are expressed in m/z values. 
 
5.4. IN VITRO STUDIES 
5.4.1 In vitro Antioxidant study 
5.4.1.1 DPPH (α, α- diphenyl -β- picryl hydrazyl) Free Radical Scavenging Assay 
Principle 
       The molecule of 1, 1-diphenyl-2-picrylhydrazyl (α, α- diphenyl -β- picryl 
hydrazyl; DPPH) is characterized as a stable free radical by virtue of the 
delocalization of the spare electron over the molecule as a whole, so that the 
molecules do not dimerise, as would be the case with most other free radicals. The 
delocalization also gives rise to the deep violet colour, characterized by an absorption 
band in ethanol/methanol solution centred at about 520 nm. When a solution of DPPH 
is mixed with that of a substance that can donate a hydrogen atom, then this gives rise 
to the reduced form with the loss of this violet colour (although there would be 
expected to be a residual pale yellow colour from the picryl group still present). 
Representing the DPPH radical by Z• and the donor molecule by AH, the primary 
reaction is   
                                                 Z•+ AH = ZH + A•. 
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Procedure
[59] 
The antioxidant activity of the compound was measured in terms of hydrogen 
donating or radical scavenging ability using the stable DPPH radical (Blois 
method).0.3mM solution of DPPH in methanol was prepared and 1ml of this solution 
was added to 1ml of various concentrations of sample and the reference compound 
(10, 20, 30, 40 and 50 μg/ml), were shaken vigorously and left to stand in the dark at 
room temperature for 30 min and then absorbance was measured at 517 nm against a 
blank. Reference compound used here was ascorbic acid. A control reaction was 
carried out without the test sample. All the tests were performed in triplicate in order 
to get the mean values. The percentage of inhibition was calculated by comparing the 
absorbance values of the control and test samples. Antiradical activity was expressed 
as percentage inhibition (I %) and calculated using the following equation: 
 
Percentage inhibition (I %) = (Abs of control- Abs of sample) X 100 
                                                       (Abs of control) 
Different sample concentrations were used in order to obtain calibration curves and to 
calculate the IC50 values. (IC50 - concentration required to obtain a 50% radical 
scavenging activity). 
 
5.4.1.2 ABTS [2, 2’-azinobis (3-ethylbenzothiazoline-6-sulfonic acid] Assay 
 
Principle 
       ABTS decolourization assay is an inhibition method. The peroxidase substrate 2, 
2’-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), forms a relatively stable 
radical (ABTS+) upon one electron oxidation. This assay is based on the scavenging 
of light by ABTS radicals. An antioxidant with an ability to donate a hydrogen atom 
will quench the stable free radical and inhibits the absorption of the radical cation 
which has characteristic long-wavelength absorption spectrum showing maxima at 
660, 734, and 820nm.The relatively stable ABTS radical has a green colour and is 
quantified spectrometrically at 734nm. 
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Procedure
[60] 
          ABTS radical scavenging activity of the compound was measured by Rice-
Evans method. ABTS was dissolved in water to a 7mM concentration. ABTS radical 
cation (ABTS+) was produced by reacting ABTS stock solution with 2.45mM 
potassium persulfate and allowing the mixture to stand in the dark at room 
temperature for 12- 16 h before use. The radical was stable in this form for more than 
2 days when stored in the dark at room temperature. For the study, ABTS solution 
was diluted with phosphate buffer saline pH 7.4 (PBS) to an absorbance of 0.70 (± 
0.02) at 734nm and equilibrated at 30
o
C. After addition of 1ml of diluted ABTS 
solution to various concentrations of sample or reference compound (ascorbic acid), 
the reaction mixture was incubated for 6min and then absorbance was measured at 
734 nm against a blank. A control reaction was carried out without the sample. All the 
tests were performed in triplicate in order to get the mean values. The percentage 
inhibition of ABTS by the sample was calculated according to the formula: 
 
Percentage inhibition (I %) = (Abs of control- Abs of sample) X 100 
                                                        (Abs of control) 
Different sample concentrations were used in order to obtain calibration curves and to 
calculate the IC50 values. (IC50 - concentration required to obtain a 50% radical 
scavenging activity). 
 
5.5 IN VITRO CYTOTOXICITY ASSAY (MTT ASSAY)
[61,62] 
Cell line used 
    The human colon cancer cell line (HT-29) was obtained from National Centre for 
Cell Science (NCCS), Pune and grown in Eagles Minimum Essential Medium 
containing 10% foetal bovine serum (FBS). The cells were maintained at 37
0
C, 5% 
CO2, 95% air and 100% relative humidity. Maintenance cultures were passaged 
weekly, and the culture medium was changed twice a week. 
Cell treatment procedure 
       The monolayer cells were detached with trypsin-ethylenediamine tetraacetic acid 
(EDTA) to make single cell suspensions and viable cells were counted using a 
hemocytometer and diluted with medium containing 5% FBS to give final density of 
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1x10
5
 cells/ml. One hundred microlitres per well of cell suspension were seeded into 
96-well plates at plating density of 10,000 cells/well and incubated to allow for cell 
attachment at 37
0
C, 5% CO2, 95% air and 100% relative humidity. After 24 h the cells 
were treated with serial concentrations of the test samples. They were initially 
dissolved in neat dimethylsulfoxide (DMSO) and an aliquot of the sample solution 
was diluted to twice the desired final maximum test concentration with serum free 
medium. Additional four serial dilutions were made to provide a total of five sample 
concentrations. Aliquots of 100 µl of these different sample dilutions were added to 
the appropriate wells already containing 100 µl of medium, resulting in the required 
final sample concentrations. Following sample addition, the plates were incubated for 
an additional 48 h at 37
0
C, 5% CO2, 95% air and 100% relative humidity. The 
medium containing without samples were served as control and triplicate was 
maintained for all concentrations.  
MTT assay 
3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) is a yellow water 
soluble tetrazolium salt. A mitochondrial enzyme in living cells, succinate-
dehydrogenase, cleaves the tetrazolium ring, converting the MTT to an insoluble 
purple formazan. Therefore,the amount of formazan produced is directly proportional 
to the number of viable cells. 
                              Structures of MTT and colored formazan product. 
 
After 48 h of incubation, 15µl of MTT (5mg/ml) in phosphate buffered saline (PBS) 
was added to each well and incubated at 37
0
C for 4h. The medium with MTT was 
then flicked off and the formed formazan crystals were solubilized in 100µl of DMSO 
Succinate -
dehydrogenase 
D  
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and then measured the absorbance at 570 nm using micro plate reader. The % cell 
inhibition was determined using the following formula.  
% Cell Inhibition =  100  -   (Abs of sample) x 100 
                                   (Abs of control) 
 
Nonlinear regression graph was plotted between % Cell inhibition and Log 
concentration and IC50 was determined using GraphPad Prism software. 
5.6  IN VIVO ANIMAL STUDY 
TOXICOLOGICAL EVALUATION OF SYNTHESISED COMPOUND 
1. ACUTE ORAL TOXICITY STUDY 
        Acute oral toxicity refers to those adverse effects occurring following oral 
administration of a single dose of a substance or multiple doses given within 24 hours 
to the animals. 
Table 3: Test substance details 
Name Pyrazolo benzpyridazine(Pz-5) 
Colour Yellow colour 
Nature Dry powder 
 
Table 4:  Experimental protocol 
Name of the study Acute toxicity 
Guideline followed OECD 423 method – Acute toxic class method. 
Animals Healthy young adult albino Wistar rat, nulliparous, 
non –pregnant. 
Body weight & sex 150-200 g & Female 
Administration of dose 5,50,300,2000mg/kg 
Route of administration Oral by using rat oral feeding needle 
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Vehicle Carboxy methyl cellulose (CMC) 
Room temperature 22ºc±3ºc 
Humidity 45-55% 
Light 12h:12h (light:darkcycle) 
Feed Standard laboratory animal food pellets with water ad 
libitum 
 
After administration of the drug, food is withheld for further 1-2 hours. The time of 
death if any, is recorded. 
Table 5: Study period and observation parameters 
Initial observation First 30 minutes and periodically 24 hr 
Special attention First 1-4 hr after drug administration 
Long term observation Upto 14 days 
Direct observation parameters Tremors, convulsions, salivation, diarrhoea, 
lethargy, sleep and coma. 
Additional observation parameters Skin and fur, eye and mucous membrane, 
respiratory, circulatory, autonomic and 
central nervous systems, somatomotor 
activity and behaviour patterns  
Study procedure. 
Acute oral toxicity was performed as per Organization for Economic co-operation for 
development (OECD) guideline 423 methods. Following the period of fasting, 
animals were weighed and test substance was administered orally through gavage 
using specially designed rat oral needle. After the administration of test substance, 
food was withheld for 2 hours but not water. Animals are observed individually after 
at least once during the first 30 minutes, periodically during the first 24hrs, with 
special attention given during the first 4 hours, and daily thereafter, for a total of 14 
days. Those animals which are found dead or in extreme distress if any are removed 
and humanely killed for animal welfare reasons.
[63] 
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5.7 EVALUATION OF ANTICANCER ACTIVITY OF VASCULAR 
ENDOTHELIAL GROWTH FACTOR RECEPTOR(VEGFR) 
INHIBITORS ON DMH INDUCED COLON CARCINOMA 
5.7.1 Selection of animals for the study 
Table 6: Selection of animals for pharmacological evaluation 
Species Sprague Dawley 
Age 50 days 
Body weight 80-100 gm 
Gender Female 
ANIMALS AND MANAGEMENT 
Female Sprague-dawley rats 50 days of age, and 80-100 g body weight were offered 
by KMCH College of Pharmacy, Coimbatore. All the rats were kept at room 
temperature and allowed to acclimate in standard conditions under 12 hours light/ 12 
hours dark cycle in the animal house. Animals are fed with commercial pellet diet and 
water ad libitum freely throughout the study. The experimental procedure was 
approved by IAEC (Institution of Animal Ethical Committee) of KMCH governed by 
CPCSEA, Government of India. Proposal number: KMCRET/M.Pharm/05/2014-15. 
5.7.2 Experimental design 
                     Table 7:Experimental design for the study 
Group No of animals Group Specification 
Group I 6 Normal Control 
Group II 6 Only DMH(20 mg/kg) 
Group III 6 DMH+ Standard (5-FU,20 mg/kg) 
Group IV 6 DMH+ Compound PZ-5 
(Low dose-100 mg/kg) 
Group V 6 DMH+  Compound PZ-5 
(High  dose- 200 mg/kg) 
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5.7.3 Induction of Colon cancer using DMH
[64] 
PRINCIPLE 
 1,2-Dimethyl hydrazine(DMH), a potent colon specific carcinogen and an 
alkylating agent can cause colon cancer in a reproducible in vivo experimental 
system for studying non-familial forms of colon carcinoma. 
 In which, DMH will be converted to diazonium ions,azoxymethane(AOM) 
and methylazoxymethanol(MAM) in presence of NAD
+ 
-dependent 
dehydrogenase enzyme.These intermediates alkylate colonic mucosal DNA 
and results in oxidative stress followed by delayed repair of damaged DNA 
leads to the accumulation of multiple mutations such as Apc,K-ras,b-catenin 
and thus leads to susceptibility of specific adenocarcinoma of colon. 
 Experimental colon cancer induced by DMH in rats mimics human colon 
cancer  and is therefore, an ideal model for chemoprevention studies. 
Requirements 
Table 8: Requirements for induction of cancer 
Carcinogen 1,2-Dimethyl hydrazine 
Dose 20 mg/kg 
Solvent 0.9 % sodium chloride 
Alkalinisation  Sodium hydroxide  
Cleaning solution Sodium carbonate 
 
a. Preparation and induction of DMH solution: 
The DMH was purchased from sigma chemicals, Mumbai, India and was stored 
according to the manufacturer label (2-8
0 
C) to prevent its decomposition. The DMH 
solution was freshly prepared at 20 mg/kg. The DMH was dissolved in 1 mMol/L 
EDTA-normal saline; the pH was adjusted to 6.5 with 1 Mol/L NaOH to ensure the 
pH suitability and the stability of the chemical. The resultant solution of the 
carcinogen was used immediately after preparation. DMH was injected 
subcutaneously (s.c.) at a dose of 20mg/kg/body weight once a week for ten 
consecutive weeks on the dorsal back of the animal. 
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b. Clean up following injection: 
After DMH induction the excess amount of DMH and the prepared area were cleaned 
and chemically inactivated by using a dilute solution of sodium carbonate. Materials 
used during carcinogen administration were disposed by incineration in compliance 
with institution biosafety guidelines.  
c. Preparation of 5-Fluorouracil solution. 
20mg/kg was dissolved in 10 ml of 1 % CMC as vehicle was freshly prepared daily 
and given via orally to the standard group. 
d. Preparation of sample: 
100 mg /kg and 200 mg/kg of test compound Pz-5 were dissolved in 1% CMC and it 
was prepared freshly and given via oral route to group IV& V respectively. 
5.7.4 Determination of body weight 
[64] 
 All the rats were weighed for every 7 days after tumour inoculation. Average gain in 
body weight was determined and recorded.  
5.7.5 Estimation of Tumerogenesis 
5.7.5.1 Estimation of Tumour Burden 
[64] 
Number of tumours formed in each animal is called tumour burden. It is also find out 
by dissection of animals on final day of study. 
5.7.5.2 Estimation of Tumour Weight 
Tumour weight was estimated according to the method of Geren et al. The   resultant 
solid tumor was considered to be prelate ellipsoid with one long axis and two short 
axis. The tumour weight was calculated by measuring the weight of colon 
(approx.10cm). 
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5.7.6 Estimation of hematological parameters 
 Blood collection 
After the end of the treatment period (ie. 30days) the animals were anaesthesised with 
ketamine (i.p route) and its blood was collected by retro orbital puncture with addition 
of EDTA for the enumeration of blood cells ie, RBC, WBC and estimation of 
haemoglobin.  The estimation of various biochemical parameters carried out by using 
blood sample without adding EDTA.  
Separation of serum 
For the estimation of the biochemical parameters such as Alkaline phosphatase 
(ALP), Serum glutamate oxaloacetate transaminase (SGOT), Serum glutamate 
pyruvate transaminase (SGPT), Serum creatinine and total protein. The serum was 
separated from the blood by centrifuging at 10,000 rpm for 10 minutes. The separated 
serum was collected and used for the estimation of parameters.  
5.7.6.1 Enumeration of red blood cells (RBC)
 [65] 
Requirements 
 RBC diluting fluid (Hayem’s fluid) 
 Counting chamber (Neubauer’s chamber) 
 RBC pipette 
 Microscope with 45 X lens 
Procedure 
The RBC pipette was filled with blood upto the mark 0.5. RBC diluting fluid 
(Hayem’s fluid) was filled upto the mark 101. The pipette was rolled between the 
palms to ensure thorough mixing of blood with diluting fluid and kept for sometime. 
The counting chamber was placed and the RBC squares were focussed under low 
power and after identification of the markings turn to high power. The first 3-4 drops 
of blood mixture was discarded and it was mixed once again. The counting chamber 
was charged with the mixed blood. After that mount the slide and allowed the fluid to 
settle down by using a 45 X lens. The RBC was counted in the corner and middle 
squares. The number of cells were expressed as 10
6
cells/mm
3
. 
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5.7.6.2 Enumeration of white blood cells (WBC)
 [65] 
Requirements 
 WBC diluting fluid (Turk’s fluid) 
 Counting chamber (Neubauer’s chamber) 
 WBC pipette 
 Microscope with 45 X lens 
Procedure 
 The WBC pipette was filled with blood upto the mark 0.5. WBC diluting fluid 
(Turk’s fluid) was filled upto the mark 11. The pipette was rolled between the palms 
to ensure thorough mixing of blood with diluting fluid and kept for sometime. The 
counting chamber was placed and the WBC squares were focussed under low power 
and after identification of the markings turn to high power. The first 3-4 drops of 
blood mixture was discarded and it was mixed once again. The counting chamber was 
charged with the mixed blood. After that mount the slide and allowed the fluid to 
settle down by using a 45 X lens. The WBC was counted in the corner and middle 
squares. The number of cells was expressed as 10
3 
cells/mm
3 
5.7.6.3 Estimation of haemoglobin
 [65] 
Principle 
This method is based on the conversion of heamogobin to acid haematin by treatment 
with 0.1 N hydrochloric acid. The brown colour formed due to acid heamatin was 
matched against a glass standard on a comparator. 
Requirements 
 Sahil’s hemometer 
 Hb pipette 
 0.1 N HCl 
Procedure 
The heamoglobinometer tube was filled with 0.1 N HCl up to the marking 10. To this 
20 µL of blood was added by using pipette. The superfacial acid was and rinsed 
Methodology 
 
Department of Pharmacology, KMCH College of Pharmacy 81 
 
repeatedly till all the blood in the pipette washed out in the acid. Mixed thoroughly by 
stirrer and allowed to stand for 10 minutes. A clear brown colour solution was formed 
due to the formation of acid haematin. Dilute the solution by adding drop by drop of 
distilled water. The colour of the diluted solution was compared with that of standard. 
Reading was noted directly from the graduated tube as g/ 100 mL or as percentage of 
haemoglobin. 
5.7.7 Estimation of serum biochemical parameters
[66,67] 
 5.7.7.1 Estimation of alkaline phosphatase (ALP) 
Method 
Kinetic photometric test-according to IFCC (International Federation of Clinical 
Chemistry and Laboratory Medicine) 
Principle 
ALP hydrolyses P-Nitrophenylphosphate to P-Nitrophenol and phosphate. 
Reaction 
P-Nitrophenyl phosphate + H2O                       P-Nitrophenol + phosphate 
Reagents 
Table 9: Composition of ALP reagent 
   
R1 Diethanolamine 1.5Mol/L 
   
 Magnesium chloride 0.6m Mol/L 
   
R2 p-Nitrophenyl Phosphate Analogue 0.070mMol/L 
   
 Sodium azide 10 %  
Procedure 
a. Mixed 0.8 mL of reagent-1 with 0.2mL of reagent-2 in a 2mL eppendroff tube.  
Methodology 
 
Department of Pharmacology, KMCH College of Pharmacy 82 
 
b. To this added 25µL of serum.  
c. Mixed well and run the sample 
5.7.7.2 Serum glutamate oxaloacetate transaminase(SGOT) 
Principle 
                                                         SGOT 
L-aspartate + 2-oxaloglutarate                              L-Glutamate + oxaloacetate. 
  
                                                         LDH 
Oxaloacetate + NADH + H
+                                             
D- Malate + NAD
+    
This modified formula for the assay of AST/SGOT, as recommended by the IFCC 
(International federation of clinical chemistry). The IFCC reference method includes 
pyridoxal phosphate  (PP) function as coenzyme in AA transfer, therefore addition of 
PP results in increased enzyme activity. It avoids falsely low activity in samples 
containing insufficient endogenous PP, e.g. from patients with myocardial infarction, 
liver disease and intensive care patients. 
Method 
Optimized UV test according to the IFCC (International Federation of Clinical 
Chemistry and laboratory medicine) 
Table 10: Composition of SGOT reagent 
 
R1 TRIS pH7.8 80mMol/L 
 Preservatives.  
 Stabilizers.  
R2 
L-Aspartate 240mMol/L 
NADH 0.18 mMol/L 
 
  Pyridoxal-5-phosphate   
Lactate dehydrogenase ≥900U/L 
 Malate dehydrogenase ≥600U/L 
 Alpha-ketoglutarate. 12mmol/L 
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Assay procedure 
 
a. Mixed 800 µL of reagent-1 with 200 µL of reagent-2 in a 5 mL test tube  
 
b. To this added 100 µL of serum.  
 
c. Mixed well and run the sample 
 
d. The readings were taken in a semi autoanalyser(Model photometer 5010) 
 
5.7.7.3 Serum glutamate pyruvate transaminase (SGPT) 
Principle 
                                                    ALAT 
L-alanine + 2- oxoglutarate                      L-glutamate + pyruvate 
 
Pyruvate + NADH + H
+                
                  D-Lactate + NAD
+
 
Addition of pyridoxal -5-phosphate (P-5-P) stabilizes the transaminases and avoid 
falsely low values in samples containing insufficient endogenous P-5-P, e.g from 
patient with myocardial infarction, liver disease and intensive care patients. 
Method 
Kinetic UV test. According to international federation of clinical chemistry and 
laboratory medicine (IFCC) 
Reagents 
Table 11: Composition of SGPT reagent 
 
 L- alanine ≥200mMol/L 
    R1 LDH (lactate dehydrogenase) ≥1500 U/L 
 2-Oxoglutarate 15mMol/L 
    R2 NADH 1.05mMol/L 
 Pyridoxal -5-phosphate   
 Alpha-ketoglutarate >35mMol/L 
 
 Procedure 
a. Mixed 800 µL of reagent-1 with 200 µL of reagent-2 in a 5ml test tube  
b. To this added 100 µL of serum.  
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c. Mixed well and run the sample. 
d. The readings were taken in a semi autoanalyser (Model photometer 5010) 
5.7.7.4 Estimation of Creatinine 
The amount of creatinine present was estimated according to Jaffe method (modified) 
Principle 
In an alkaline medium, picric acid reacts with creatinine which forms an orange 
coloured complex with the alkaline picrate. Intensity of colour formed is measured 
which is directly proportional to the amount of creatinine present in the sample. 
Reaction 
Creatinine + Alkaline picrate                           orange coloured complex 
Requirements 
Reagent 1: Standard creatinine 
Reagent 2: Picric acid solution 
Reagent 3: Sodium hydroxide solution 
Procedure 
To 500 µL of reagent 2 and 500 µL of reagent 3 were taken in a 5 mL test tube and 
mixed. To this reagent about 100 µL of serum was added and mixed well. The 
readings were taken immediately in a semi autoanalyser (Model photometer 5010).
 
5.7.7.5 Estimation of Total protein 
The amount of protein was determined by biuret method. 
Principle 
Protein forms coloured complexes with cupric ions in alkaline medium 
Reagents 
Reagent 1  
Cupric sulphate – 6 mmol/L 
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Potassium iodide- 15 mmol/L 
Reagent 2 
Protein (standard)- 6g/100 mL 
Procedure 
To 1 mL of reagent 1 in a 5 mL test tube was added 20 µL of serum and mixed well 
and incubated at a room temperature for 15 minutes and read the absorbance.
 
5.7.8 IN VIVO antioxidant activity 
Requirements 
Saline 
Disodium hydrogen phosphate 
Potassium dihydrogen phosphate 
Sodium chloride 
Preparation of 0.1M Phosphate buffer saline buffer(pH– 7.4) 
2.38g Disodium hydrogen phosphate,0.19g potassium dihydrogen phosphate and 8g 
sodium chloride were weighed and dissolved in distilled water and the volume was 
made up to 1000ml. 
Preparation of homogenate 
After blood samples were withdrawn, SD rats were sacrificed by an excessive dose of 
anesthetic ether and colons were dissected out and perfused with an ice cold saline 
transcardially. From this approx.1.5gms of colon was weighed. To this 20 ml of the 
buffer (0.1M PBS) was added. It was homogenized with motor driven Teflon coated 
homogeniser (RQ-127A, REMI MOTORS group, Mumbai,Maharashtra, India) in an 
ice cold condition. It was centrifuged at 1000rpm for 10 minutes at 4 ºC. The 
supernatant was collected and used for the in vivo antioxidant activity estimation.The 
homogenate was used for the following estimations, namely, GSH, catalase, SOD, 
GPx, Lipid peroxidation. 
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5.7.8.1 Estimation of Catalase
[67] 
The activity of catalase was assayed by the method of Beers and Sizer et al, 1952. 
Requirements 
Dichromate Acetic acid Reagent 
0.01M Phosphate Buffer (pH-7.0) 
0.2M Hydrogen peroxide. 
Principle 
The normal antioxidant activity of the enzyme catalase is due to acceleration of 
decomposition of hydrogen peroxide to water and oxygen. This method is based on 
the principle of measuring the rates of decomposition of hydrogen peroxide by the 
enzyme catalase by measured spectrophotometrically at 570 nm, since hydrogen 
peroxide has the absorbance at this range. 
                                              2H2O2                         2H2O + O2 
Procedure 
To one ml of tissue homogenate, 4 ml of hydrogen peroxide and 5 ml of phosphate 
buffer was added and mixed. From this one ml of solution was taken and mixed with 
Dichromate acetic acid reagent and allowed to incubate for 30 minutes at room 
temperature. The absorbance was measured at 570 nm. The activity of catalase was 
expressed as µmole of H2O2 consumed/min/mg protein.
 
5.7.8.2 Estimation of superoxide dismutase (SOD) 
The activity of the superoxide dismutase was assayed by the method of Fridvich 
et.al.
[67] 
Requirements 
Adrenaline 
Carbonate Buffer (pH-10.2) 
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Principle 
Pyrogallol autoxidizes rapidly in aqueous solution, where the reaction will be faster at 
higher pH, and leads to the formation of several intermediate products. Thus the 
solution first becomes yellow-brown with a spectrum between 400 and 425nm. 
Molecular oxygen, carrying two unpaired electrons with parallel spins, has a 
preference for univalent reduction because spin restrictions arise when reduction with 
electron pairs is attempted. The recently discovered enzyme superoxide dismutase 
rapidly dismutases univalently reduced oxygen O2.
-
 i.e., the superoxide anion radical 
(2O2.
-
+    2 H
+
           O2+ H2O2). The enzyme has proven to be a useful probe for 
studying the participation of the radical in reactions involving oxygen such as 
autooxidations. Thus O2
-
. has been shown to be involved in the auto-oxidation of 
sulphite, adrenalin  and 6-hydroxydopamine. 
Procedure 
5% homogenate was mixed with 75 Mm Tris-HCL (pH 8.2), 30 mM EDTA, and 2 
mM pyrogallol respectively. Then, the absorbance was measured at 420 nm. The 
percentage of inhibition was calculated depending on that the ability of enzyme to 
inhibit oxidation.The antioxidant activity of SOD enzymes was expressed as 
units/min/mg protein. 
5.7.8.3 Estimation of glutathione peroxidase (GPx) 
The activity of the Glutathione peroxidise was assayed by the method of Paglia and 
valentine et.al. 1967. 
Requirements 
0.32 M Phosphate buffer, pH 7.0 
0.8Mm EDTA 
10 Mm sodium azide 
3 Mm reduced glutathione 
2.5mM Reduced H2O2 
10 percentage TCA 
0.3 M Disodium hydrogen phosphate 
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DTNB Solution (40 mg of DTNB in 100 ml of 1% sodium citrate) 
Reduced glutathione 
Principle 
This assay is based on the principle reduction of hydrogen peroxide (H2O2) by 
gluthathione peroxidise through simultaneous oxidizing of reduced glutathione (GSH) 
to form oxidized glutathione (GSSG).GSSG is further then reduced by glutathione 
reductase (GR) and β-nicotinamide adenine dinucleotide phosphate (NADPH) 
forming NADP+ which resulting in decreased absorbance at 340 nm and recycling the 
GSH. The decrease in absorbance at 340 nm is directly proportional to the GPx 
concentration. 
Procedure 
To 0.1 ml of the tissue homogenate, 0.2 ml of EDTA, Sodium azide, hydrogen 
peroxide were added and mixed. Then 0.4 ml of phosphate buffer was added and 
allowed to incubate at room temperature. The reaction was arrested by the addition of 
0.5 ml of TCA .The reaction mixture was centrifuged at 2000 rpm and supernatant 
was collected. To 0.5 ml of the supernatant 4 ml of disodium hydrogen phosphate and 
0.5 ml of DTNB were added and the colour developed was read immediately at 420 
nm .The activity of glutathione peroxidise was expressed as µ moles of glutathione 
oxidized/min/mg.
 
5.7.8.4 Estimation of reduced glutathione (GSH) 
The activity of reduced glutathione was assayed by the method of Anderson (1985). 
Requirements 
10% TCA 
0.6 mM 5, 5’-dithiobis-2-nitrobenzoic acid (DTNB) in 0.2 M sodium phosphate 
0.2 M Phosphate buffer, pH 8.0 
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Principle 
DTNB is a disulfide compound, which was reduced by sulphadryl groups present in 
GSH. This reduction leads to the formation of yellow colour, which was measured at 
412 nm. 
Procedure 
To 1 ml of the homogenate, 1 ml of the TCA solution was added and centrifuged. The 
supernatant was collected and the precipitate formed was removed. To 0.5 ml of 
supernatant 2 ml of DTNB was added, the volume was made up to 3 ml with 
phosphate buffer. Then absorbance was read at 412 nm .The amount of glutathione 
was expressed as µ/mg protein.
 
 5.7.8.5 Determination of lipid peroxidation 
Lipid peroxidation was measured by the modified method of Ohkawa et.al.
[67]
  
Requirements 
Thiobarbituric acid 0.37 
0
/0 
0.25 N HCl 
15 
0
/0 TCA 
Principle 
This assay is based on the reduction between thiobarbituric acid with 
malonyldialdehyde which is a formed as a result of polyunsaturated fatty acid 
oxidation.This reaction leads to the formation of pink colored TBA-MDA complex 
which is measured at 532 nm. 
Procedure 
To 0.1 ml of sample, 2 ml of TBA-TCA-HCl reagent (ratio of 1:1) was added mixed 
and kept in a water bath for 15 minutes. Afterwards the solution was cooled and 
supernatant was removed and absorbance was measured at 535 nm against reference 
blank. The level of lipid peroxides was given as nm moles of MDA formed/mg 
protein.
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5.7.8.6 Estimation of proteins 
 Protein was estimated by the method of Lowry et.al 
[67] 
Requirements 
Alkaline copper reagent 
Solution A: 2 
0
/0 sodium carbonate in 0.1 N NaoH. 
Solution B: 0.5 
0
/0 copper sulphate in 1 
o
/o sodium potassium tartarate  50 ml of 
solution A was mixed with 1 ml of solution B just before use. 
Folin’s phenol reagent (commercial reagent, 1:2 dilutions), 
Bovine serum albumin (BSA). 
Principle 
This method is a combination of both Folin-ciocalteau and biuret reaction which 
involves two steps 
Step: 1 
Protein binds with copper in alkaline medium and reduces it to Cu
++
. 
Step: 2 
The Cu++ formed catalyses the oxidation reaction of aromatic amino acid by 
reducing phosphomolybdotungstate to heteropolymolybdanum ,which leads to 
the formation of blue colour and absorbance was measured at 640 nm. 
Procedure 
To 0.1 ml of the homogenate, 0.9 ml of water, 4.5 ml of alkaline copper sulphate 
reagent were added and allowed to stand in the room temperature for 10 minutes. To 
this 0.5 ml of Folin’s reagent was added. After 20 minutes, the colour developed was 
measured at 640 nm. The level of protein present was expressed as mg/g/ tissue or 
mg/dl.
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5.7.9 Estimation of mitochondrial TCA cycle enzymes activity 
Isolation of mitochondria 
The isolation of mitochondria and microsomes was carried according to the method of 
Johnson and Lardy et.al (1967) and Hanioka et.al (1997) respectively. 
Requirements 
0.05 M Tris –HCl buffer, pH 7.4 containing 0.25 M sucrose. 
0.05 M Tris – HCl buffer, pH 7.4 containing 0.15 M potassium chloride. 
Preparation of homogenate (20 
0
/0) 
The isolated kidney and liver was washed with saline solution. From this 2 gms of 
kidney and liver was weighed. To this 20 ml of the buffer (0.05 M Tris –HCl 
containing 0.25 M sucrose) was added. It was homogenized with motor driven Teflon 
coated homogenizer in an ice cold condition. It was centrifuged at 1000 rpm for 10 
minutes at 4 
0
 C. The supernatant was collected again it was centrifuged at 600 x g for 
10 minutes .The supernatant was collected and centrifuged again at 1500 x g for 5 
minutes, which results in the formation of the mitochondrial pellet. The pellet formed 
was washed and suspended in the same buffer. The suspended pellet was centrifuged 
again at 105,000 x g for 60 minutes, the supernatant solution was decanted and the 
resultant pellet was again re suspended in the 0.05 M Tris buffer containing 0.15 M 
KCl. 
5.7.9.1 Assay of succinate dehydrogenase 
The enzyme activity was assayed according to the method of Slater and Bonner 
(1952). 
Requirements 
0.3 M Phosphate buffer, pH 7.6 
0.03 M EDTA 
0.03 M Potassium cyanide 
0.4 M Succinate 
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3 % Bovine serum albumin 
0.075 M Potassium ferricyanide 
Procedure 
To 1 ml of phosphate buffer, 0.1 ml of EDTA, 0.1 ml of bovine serum albumin, 0.3 
ml of sodium succinate ,0.2 ml of potassium ferricyanide were added mixed and the 
final volume was made up to 2.8 ml with water. To this reaction mixture 0.2 ml of 
mitochondrial suspension was added immediately before measuring the absorbance 
allowed .The change in absorbance was recorded for 5 minutes with 15 seconds 
interval at 420 nm. The succinate dehydrogenase activity was measured as µ moles of 
succinate oxidized/min/mg protein.
92 
5.7.10 Histopathology of Colon Tumour 
              Histopathology is the microscopical study of tissues for pathological 
alterations. This involves collection of morbid tissues from biopsy or necropsy, 
fixation, preparation of sections, staining and microscopical examination. 
Collection of materials 
   Thin pieces of 3 to 5 mm thickness were collected from tissues showing gross 
morbid changes along with normal tissue. 
Fixation 
 Kept the tissue in fixative for 24 – 48 hr at room temperature. 
 The fixation was useful in the following ways: 
 Serves to harden the tissue by coagulating the cell protein. 
 Prevents autolysis 
 Preserves the structure of the tissue 
 Prevents shrinkage 
 Common fixative: 10%Formalin 
5.7.10.1 Haematoxylin and eosin method of staining  
    Deparaffinised the colonic section by xylol 5 to 10 minutes and removed xylol by 
absolute alcohol. Then cleaned the section in tap water and stained with haematoxylin 
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for 3-4 minutes and again cleaned under tap water. Allow the sections in tap water for 
few minutes and counter stained with 0.5 % eosin until section appears light pink (15 
to 30 seconds) and then washed in tap water. Blottedand dehydrated in alcohol and 
cleared with xylol (15 to 30 seconds).Mounted on a Canada balsam or DPX mountant 
and kept the slide dry and remove air bubbles. 
5.7.10.2 Immunohistochemistry by COX 2 Expression Study 
The pretreated paraffinised colon sections were kept in poly –L-lysine coated slides 
and these section slides  were placed into antigen retrival pretreatment.After the 
pretreatment, the slides were placed in to the solution jar containing buffer.Covered 
the pretreated slides with peroxidase blocking agent and incubated for ten minutes.The 
slides were  washed with deionised water and buffer solution periodically.Then 
covered the section with power blocking solution and incubated it for 10minutes 
followed by continued washing with buffer solution and 3 changes into it.The 
pretreated colon sections were covered with primary antibody which are used for 
process(COX-2) and incubated the sections for 30minutes,again  washed with buffer 
solutions with three changes. Then added secondary antibody and incubated for 
30minutes in room temperature. Washed with buffer solutions 3 times and then 
placed the slides into substrate DAB solution for ten minutes. Then stained the slides 
with counter stain haematoxylin solution. Dried and mounted the slides for 
microscopic observation and placed in to pathologist table. The test results were 
obtained from microscopically by pathologist.  
5.7.12 Statistical analysis 
The data were analyzed by using GRAPH PAD PRISM, VERSION 6.05, analysis of 
variance (ANOVA) followed by Dunnet’s and Turkey’s multiple comparison of all 
pairs of columns test was performed.  
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6. RESULTS AND DISCUSSION 
IN SILICO STUDIES 
LEAD OPTIMISATION 
 Lead optimization aims at enhancing the most promising compounds to improve 
effectiveness, diminish toxicity, or increase absorption. Many of the technologies for lead 
discovery overlap with lead optimization as researchers attempt to incorporate the best drug 
characteristics early in the process. While the approaches taken may vary, the central theme is 
the same: make it better, faster, and more efficient.                                
                  Druglikeness is a qualitative concept used in drug design for how "druglike" a 
substance is with respect to factors like bioavailability. It is estimated from the molecular 
structure before the substance is even synthesized and tested. 
Table 12: Druglikeness Molecular properties (Molinspiration) table (Lipinski Rule 
Table) 
 
                    
 
                
  
Compound 
code 
Mol. 
Wt 
Log P 
No of H 
Donors 
No of H 
acceptors 
No of 
violations 
Mol. 
Polar 
Surface 
Area 
Pz-1 218.65 2.594 1 3 0 54.46 
Pz-2 294.75 3.94 0 3 0 
43.6 
Pz-3 278.29 3.42 0 4 0 
43.6 
Pz-4 305.30 3.22 1 5 0 
100.28 
Pz-5 263.28 0.61 1 6 0 
123 
Pz-6 339.38 1.95 0 6 0 
112.14 
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ADME Properties predictions 
Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties of drug 
candidates or environmental chemicals play a key role in drug discovery and environmental 
hazard assessment. All the synthesised benzpyridazine derivatives were subjected to ADME 
Properties predictions using ADMESAR software, and the predicted Absorption and 
Distribution properties are given in table: 13 and the predicted metabolic properties are given 
in table:14. 
 Table 13: Absorption and Distribution Properties Prediction using ADMESAR 
 
Compound 
code 
Blood-Brain 
Barrier 
Human Intestinal 
Absorption 
Caco-2       
Permeability 
LogPapp, 
cm/s 
 
P-glycoprotein 
Substrate 
PZ-1 BBB+ HIA+ Caco2- 1.0776 Non-substrate 
PZ-2 BBB+ HIA+ Caco2+ 1.4446 Non-substrate 
PZ-3 BBB+ HIA+ Caco2+ 1.3634 Non-substrate 
PZ-4 BBB+ HIA+ Caco2+ 1.0872 Non-substrate 
PZ-5 BBB+ HIA+ Caco2+ 0.9354 Non-substrate 
PZ-6 BBB+ HIA+ Caco2- 0.5929 Non-substrate 
 
Caco-2 & LogPapp -   In vitro model of the human small intestinal mucosa to predict the 
absorption of orally administered drugs.  
P-glycoprotein- ATP- dependent efflux pump with broad substrate specificity. 
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Table 14:  Metabolic properties predictions of synthesised benzpyridazine derivatives 
Compound 
code 
CYP450 2D6 
Substrate 
CYP450 2D6 
Inhibitor 
CYP450 2C9 
Substrate 
CYP450 2C9 
Inhibitor 
PZ-1 Non-substrate Non-inhibitor Non-substrate Non-inhibitor 
PZ-2 Non-substrate Non-inhibitor Non-substrate Inhibitor 
PZ-3 Non-substrate Non-inhibitor Non-substrate Inhibitor 
PZ-4 Non-substrate Non-inhibitor Non-substrate Non-inhibitor 
PZ-5 Non-substrate Non-inhibitor Non-substrate Non-inhibitor 
PZ-6 Non-substrate Non-inhibitor Non-substrate Non-inhibitor 
 
CYP450 2D6 & CYP450 2C9  - a member of  the cytochrome P450 mixed-function oxidase 
system, involved in the metabolism of xenobiotics in the body. 
 
 
TOXICITY STUDIES 
PROTOX is a webserver for the prediction of oral toxicities of small molecules in rodents. 
The medial lethal dose (LD50) and the toxicity class is calculated for an input compound 
based on chemical similarites to toxic compounds. All the synthesised benzpyridazine 
derivatives were subjected to oral toxicities predictions using PROTOX software, and the 
compounds were found to be within the applicable range and the predicted toxicity properties 
are given in table:15. 
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 Table 15 : Oral toxicity properties predictions of synthesised benzpyridazine     
derivatives 
AD- applicable domain 
 
 
 
 
 
S
l.
 N
o
 
C
o
m
p
o
u
n
d
 c
o
d
e 
P
re
d
ic
te
d
 O
ra
l 
to
x
ic
it
y
 
L
D
5
0
 v
al
u
e 
m
g
/k
g
 
P
re
d
ic
te
d
 
T
o
x
ic
it
y
 C
la
ss
 
T
o
x
 r
el
at
ed
 f
ra
g
m
en
ts
 
T
o
x
ic
it
y
 t
ar
g
et
s 
b
in
d
in
g
[A
A
2
A
R
, 
A
D
R
B
2
, 
A
N
D
R
, 
A
O
F
A
, 
C
R
F
R
1
D
R
D
3
, 
E
S
R
1
, 
E
S
R
2
, 
G
C
R
, 
H
R
H
1
, 
N
R
1
I2
, 
O
P
R
K
, 
O
P
R
M
, 
P
D
E
4
D
, 
P
G
H
1
, 
P
R
G
R
] 
R
at
 I
P
 L
D
5
0
 (
m
g
/k
g
) 
R
at
 I
V
 L
D
5
0
 (
m
g
/k
g
) 
R
at
 O
ra
l 
L
D
5
0
 (
m
g
/k
g
) 
R
at
 S
C
 L
D
5
0
 (
m
g
/k
g
) 
1 PZ-1 1000 4 
No 
toxicity 
Fragments 
No Binding 265,200 110,500 778,000 
48
8,3
00 
2 PZ-2 1680 4 
No  
toxicity  
Fragments 
No Binding 382,100 124,700 1520,000 
11
58,
00
0 
3 PZ-3 1680 4 
No  
toxicity  
Fragments 
No Binding 353,300 180,600 979,200 
56
4,7
00 
4 PZ-4 2200 5 
No  
toxicity  
Fragments 
No Binding 591,400 124,000 547,700 
26
5,4
00 
5 PZ-5 295 3 
No  
toxicity  
Fragments 
No Binding 916,500 881,000 4298,000 
13
27,
00
0 
6 PZ-6 1680 4 
No  
toxicity  
Fragments 
No Binding 979,100 617,900 4484,000 
15
78,
00
0 
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Eco-toxicity predictions 
GUSAR has been developed according to OECD principles and includes last achievements in 
the field of QSAR modeling. Quantitative prediction of ecotoxicity for chemical compounds 
by GUSAR software was utilised for predicting the Ecotoxicity of the designed molecules. 
The QSAR models were developed for the following endpoints: 96 hr fathead minnow 50% 
lethal concentration, 48 hr daphnia magna 50% lethal concentration, Tetrahymena pyriformis 
50% growth inhibition concentration and Bio concentration Factor. All the synthesised 
compounds fall in applicable range. All the synthesised benzpyridazine derivatives were 
subjected to eco-toxicities predictions using GUSAR software, and the predicted toxicity 
properties are given in table:16. 
          Table 16: Environmental Toxicity predictions report. 
Comp. 
 code 
Predicted activity 
Biodegradation 
Bioaccu
mulation 
factor 
Log10(B
CF) 
Daphnia 
magna 
LC50 -
Log10(
mol/L) 
Fathead 
Minnow 
LC50 
Log10 
mmol/L 
Tetrahymena 
pyriformis 
IGC50 Log10 
(mol/L) 
AMES 
Toxicity 
Carcinogens 
PZ-1 1,152 4,986 -1,218 1,392 AMES toxic 
Non-
carcinogen 
Not readily 
biodegradable 
PZ-2 1,716 5,146 -2,082 1,755 AMES toxic 
Non-
carcinogen 
Not readily 
biodegradable 
PZ-3 1,445 5,925 -1,966 1,520 AMES toxic 
Non-
carcinogen 
Not readily 
biodegradable 
PZ-4 0,812 5,119 -1,159 1,223 AMES toxic 
Non-
carcinogen 
Not readily 
biodegradable 
PZ-5 0,467 4,418 -0,244 0,711 
Non-AMES 
toxic 
Non-
carcinogen 
Not readily 
biodegradable 
PZ-6 0,596 5,337 -1,210 0,848 
Non-AMES 
toxic 
Non-
carcinogen 
Not readily 
biodegradable 
 
Bioaccumulation  is the uptake of organic compounds by biota from either water or food. 
Daphnia magna-Waterflea 
 
 
 MOLECULAR DOCKING 
 
 A library of 54 compounds that contain pyrazolo benzpyridazine derivatives were made, then 
these compounds were optimized and docked into the active pocket of VEGFR2 protein 
(PDB code: 3VO3) using the glide program, in order to make a pre-selection of promising 
compounds.The maestro user interface (version 10.1,Schrodinger, LLC, New York,2015) 
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was employed to set up and execute the docking protocol and also for analysis of the docking 
results.According to their docking scores and their interaction with VEGF receptor, the 
selection of the compounds were made and synthesized. The Docking studies of designed 
pyrazolo pyridazine compounds with VEGFR(3VO3) are given in the table: 17. 
        The amino acid interaction studies of the selected compounds were carried out and are 
given in table: 18. From the docking studies, compound PZ-5 having good glide score and 
amino acid interaction with Cys919 of 3VO3 as like standard ligand. The docking and 
aminoacid interactions of selected compounds (PZ-1 to PZ-6) were shown in figure 24-33. 
Table 17: Docking studies of designed pyrazolo pyridazine compounds with VEGFR 
Designed 
Lead Code 
Bpp 
GLIDE 
Score 
Lipophilic 
EvdW 
PhobEn PhobEnHB 
PhobEnPair 
HB 
HBond 
1 -7.25 -5.22 -0.93 0 0 -0.7 
2 -6.95 -5.42 -1.18 0 0 0 
3 -6.91 -4.91 -1.15 0 0 0 
4 -6.8 -5.26 -1.1 0 0 0 
5 -6.75 -3.23 -0.53 0 -1.22 -0.93 
6 -6.74 -  3.19 -0.53 0 -1.23 -0.94 
7 -6.72 -5.35 -0.97 0 0 0 
8 -6.64 -3.15 -0.53 0 -1.14 -0.99 
9 -6.62 -3.4 0 0 -1.5 -0.93 
10 -6.55 -4.44 -1.3 0 0 0 
11 -6.53 -4.09 -1.27 0 0 0 
12 -6.58 -2.67 0 -1.5 0 -1.32 
13 -6.48 -5.01 -0.88 0 0 0 
14 -6.38 -3.17 -0.53 0 -0.91 -0.9 
15 -6.34 -4.63 -0.95 0 0 0 
16 -6.37 -5.08 -0.8 0 0 0 
17 -6.3 -3.14 -0.53 0 -0.87 -0.9 
18 -6.3 -3.24 -0.53 0 -0.94 -0.75 
19 -6.27 -3.14 -0.53 0 -1.06 -0.74 
20 -6.22 -2.93 0 0 -1.39 -1 
21 -6.21 -4.92 -0.9 0 0 0 
22 -6.2 -3.8 0 0 0 -1 
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23 -6.15 -4.88 -0.9 0 0 0 
24 -6.13 -3.49 -0.88 0 0 -0.7 
25 -6.13 -4.86 -0.9 0 0 0 
26 -6.12 -4.9 -0.85 0 0 0 
27 -6.03 -4.78 -0.93 0 0 0 
28 -6.37 -4.47 -0.97 0 0 -0.39 
29 -7.18 -5.01 -0.85 0 0 -0.89 
30 -5.91 -3.14 -0.5 0 -0.62 -0.81 
31 -5.8 -3.67 -1.18 0 0 0 
32 -5.63 -4.49 -0.75 0 0 0 
33 -5.59 -3.61 -0.3 0 0 -0.7 
34 -5.47 -3.43 -1.01 0 0 -0.22 
35 -5.39 -3.56 -0.78 0 0 -0.07 
36 -5.25 -4.33 -0.45 0 0 0 
37 -5.1 -3.11 -0.3 0 0 -0.7 
38 -5.08 -3.47 -0.28 0 0 -0.35 
39 -5.04 -4.77 0 0 0 0 
40 -5.03 -3.39 -0.28 0 0 -0.7 
41 -5.03 -3.05 -0.53 -0.23 0 -0.45 
42 -5 -3.21 -0.45 0 0 -0.66 
43 -5.32 -3.42 -0.28 0 0 -0.68 
44 -4.74 -4.25 0 0 0 0 
45 -4.73 -2.5 -0.13 0 0 -0.69 
46 -4.73 -3.76 0 0 0 -0.7 
47 -4.67 -3.23 -0.13 0 0 -0.97 
48 -5.8 -2.51 0 -1.5 0 -0.83 
49 -4.31 -3.72 -0.3 0 0 -0.68 
50 -4.29 -3.4 -0.45 0 0 0 
51 -4.76 -4 -0.53 0 0 0 
52 -4.54 -2.8 -0.33 0 0 -0.7 
53 -7.82 -3.41 -0.68 0 -1.22 -1.38 
54 -7.28 -4.81 -0.9 0 0 -0.7 
 
                Table 18: Amino acid interactions of selected compounds 
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Molecule 
Design 
Code 
Comp. 
Code 
 
GLIDE 
Dock Score 
Amino 
Acid 
Interacted 
Hydrogen 
Length 
Molecule 
Linked 
Bpp-01 Pz-1 -6.74 Cys919 2.07 Pyrazole 
Bpp-19 Pz-2 -6.72 Phe1047 1.00 
Benz-
Pyridazine 
Bpp-30 Pz-3 -6.91 
Cys919 
Phe1047 
2.45 
Pyridazine 
Pyrazole 
Bpp-28 Pz-4 -6.75 Cys919 2.39 Pyrazole 
Bpp-41 Pz-5 -7.82 Cys919 2.45 Pyrazole 
Bpp-38 Pz-6 -7.25 
Arg1032 
Arg1051 
Phe1047 
2.00 
 
Pyridazine 
 
 
Figure 24: 2D Interaction Of N-[3-({2-[(Cyclopropyl Carbonyl) Amino] Imidazo[1,2- 
B]Pyridazin-6-yl}Oxy)Phenyl]-1,3-Dimethyl- 1H-Pyrazole-5-Carboxamide With  3VO3 
 
Figure 25: 2 D Interaction of Compound PZ-1 
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Figure 26: 3 D Interaction of Compound PZ-1 
 
 
Figure 27: 2 D Interaction Of Compound PZ-2 
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Figure 28: 3 D Interaction Of Compound PZ-2 
 
 
Figure 29: 2 D Interaction Of Compound PZ-3 
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Figure 30: 2 D Interaction Of Compound PZ-4 
 
 
Figure 31: 2 D Interaction Of Compound PZ-5 
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                      Figure 32: 3 D Interaction Of Compound PZ-5 
 
Figure 33: 2 D Interaction Of Compound PZ-6 
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Figure 34: 3 D Interaction Of Compound PZ-6 
    
 
SYNTHESIS OF PYRIDAZINE DERIVATIVES 
Results and Discussion  
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The novel Benzpyridazine derivatives were designed on the basis of literature survey . 
Several compounds were hypothetically designed and performed molecular modelling studies 
by using Glide software. Based on the docking scores and feasibility of synthesis, 6 
compounds were selected and synthesized by various reaction intermediates such as 
Step 1: Synthesis of  Ethyl 3 –oxo-2-(2-substituted phenylhydrazinylidene) butanoate. 
Step 2: Synthesis of 3-Acetyl benzpyridazine-4(1H)-one derivatives. 
Step 3: Synthesis of Pyrazolo benzpyridazine derivatives. 
Physicochemical Studies of Synthesised Compounds 
Physical parameters like percentage yield, molecular weight, molecular formula, 
melting point, logP and Rfvalue of the synthesized compounds were determined and is 
given in table 19. The final compounds were in moderate to higher yields. The 
percentage yield was found to be in the range of 70 – 95 %. 
 
         Table 19: Physicochemical parameters of synthesised compounds 
 
Compound 
Code 
 
Molecular 
Formula 
 
Molecular 
Weight 
 
% 
Yield 
 
Colour 
 
Solubility 
 
M.P 
ºC 
 
 
Rf 
value⃰ 
 
PZ-1 C10H7ClN4 218.65 74.5 Orange DMSO 232 0.76 
PZ-2 C16H11ClN4 294.75 95.6 Orange DMSO 180 0.42 
PZ-3 C16H11FN4 278.29 92.3 Orange DMSO 200 0.96 
PZ-4 
C10H7N5O2 
 
305.30 78.68 Brown DMSO 100 0.61 
PZ-5 
C10H9N5SO2 
 
263.28 88.3 Yellow DMSO 210 0.21 
PZ-6 
C16H13N5SO2 
 
339.38 94.32 Yellow DMSO 200 0.73 
    * Mobile phase – Chloroform : Methanol -0.2:9.8 
 
SPECTRAL STUDIES OF SYNTHESISED COMPOUNDS 
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The structure of the synthesised compounds were compounds were confirmed by IR, NMR , 
and mass spectral analysis and  is shown in table 20.The IR ,NMR and MASS spectra of 
synthesised compounds were shown in figure 34-50. 
                Table 20: Spectral analysis of synthesised compounds 
Compound 
code 
λmax 
(nm) 
 
IR (cm-1) 
1 H NMR 
(δ ppm) 
13C NMR 
(δ ppm) 
MASS 
(m/z) 
 
 
 
 
PZ-1 
 
 
 
 
432 
2911(CH stretching) 
3162.69(NH stretching) 
1588.59(N=N 
stretching) 
1667(C=N) 
1045.71(C-N) 
900-675 (Aromatic 
group) 
3162.69(Aromatic C-H 
Stretching) 
1096 (C-Cl ) 
7.01-7.6 (Ar 
H) 
2.15(H, CH3 ) 
11.58(H, NH ) 
11.56(C of 
CH3) 
143.12-
146.97(C =N 
pyrazole ring) 
159.90 (C-C 
Cinnoline)  
129.16(C-N 
Cinnoline) 
114.41-
143.12(C of 
Aromatic ring)  
 
 
 
 
 
218.64 
 
 
 
 
 
 
PZ-2 
 
 
 
 
 
207.5 
2924.04(Aromatic CH 
stretching) 
3484.26(NH stretching) 
1618.95(N=N 
stretching) 
1468.05(C=N 
stretchimg) 
1249.16(C-N stretching) 
900-675 (Aromatic 
group) 
3162.69(Aromatic C-H 
Stretching) 
600-800 (C-Cl 
stretching ) 
7-7.48 
(Aromatic H) 
2.132(H in 
CH3 group) 
 
 
 
 
 
------ 
 
 
 
 
 
------- 
 
 
 
 
PZ-3 
 
 
 
 
272 
2926.93(Aromatic CH 
stretching) 
1614.13(N=N 
stretching) 
1561.09(C=N str) 
900-675 (Aromatic 
group) 
1400-1000 (C-F 
stretching ) 
7-7.5 
(Aromatic H) 
2.23(H in CH3 
group) 
 
 
 
 
------- 
 
 
 
 
------- 
 
Compound 
code 
 
λmax 
(nm) 
 
IR (cm-1) 
 
1 H NMR 
(δ ppm) 
 
13C NMR 
(δ ppm) 
 
MASS 
(m/z) 
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PZ-4 
 
 
 
 
207.5 
2921.63(Aromatic CH 
stretching) 
3411.46(NH stretching) 
1629.55(N=N 
stretching) 
1405.37(C=N 
stretching) 
613.735(Aromatic 
group) 
 
10.69-11.29(H 
in NH group) 
7.247-
7.97(Aromatic 
H group) 
2.022(H in 
CH3 group 
 
 
 
 
------- 
 
 
 
 
------- 
 
 
 
 
     PZ-5 
 
 
 
 
401.5 
2921.63(CH stretching) 
3411.94(NH stretching) 
1617.5(N=N stretching) 
1410.67(C=N 
stretching) 
1160.45(C-N) 
900-675(Aromatic 
group) 
3302.02(C-SO2NH2 
group) 
1334.5(SO2 stretching) 
 
 
11.618(H in 
NH group) 
7.46-7.99 
(Aromatic H 
group) 
2.17(H in CH3 
group 
11.612(C of 
CH3) 
112-145.5(C of 
Aromatic ring) 
129.306(C-N 
Cinnoline) 
146.902 
(C =N of 
pyrazole ring) 
159.993(C-C 
Cinnoline) 
 
 
 
 
 
263.75  
 
 
 
 
 
 
PZ-6 
 
 
 
 
 
272.5 
2926.93(Aromatic CH 
stretching) 
3450-3390(NH 
stretching) 
1617.98(N=N 
stretching,C=N 
stretching) 
1160.45(C-N) 
900-675(Aromatic 
group) 
3228.74(Aromatic C-
SO2 NH2  group) 
1332.57(SO2 stretching) 
 
 
7.23-7.93 
(Aromatic H 
group) 
2.33(H in CH3 
group 
11.648(C of 
CH3) 
114.47-
145.513(C of 
Aromatic ring) 
129.0346(C-N 
Cinnoline) 
145.513 
(C =N of 
pyrazole ring) 
156.327(C-C 
Cinnoline) 
 
 
 
 
 
 
------- 
 
 
 
Figure 35: IR Spectrum Of Compound PZ-1 
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Figure 36: IR Spectrum Of Compound PZ-2 
 
 
 
Figure 37: IR Spectrum Of Compound PZ-3 
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Figure 38: IR Spectrum Of Compound PZ-4 
 
 
 
                   Figure 39: IR Spectrum Of Compound PZ-5 
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                   Figure 40: IR Spectrum Of Compound PZ-6 
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              Figure 41: 1H NMR Spectrum Of Compound PZ-1 
 
 
     
                  Figure 42: 13C NMR Spectrum Of Compound PZ-1  
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                Figure 43:  Mass Spectrum Of Compound PZ-1 
 
 
 
 
 
 
     
 
 
 
 
 
             Figure 44: 1H NMR Spectrum Of Compound PZ-2  
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                Figure 45: 1H NMR Spectrum Of Compound PZ-3 
 
 
                 Figure 46: 1H NMR Spectrum Of Compound PZ-4 
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                           Figure 47: 1H NMR Spectrum Of Compound PZ-5 
 
      
 
                    Figure 48: 13C NMR Spectrum Of Compound PZ-5 
 
     
 
Figure 49:  Mass Spectrum of Compound PZ-5  
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Figure 50: 1H NMR Spectrum Of Compound PZ-6 
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Figure 51: 13C NMR Spectrum Of Compound PZ-6 
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IN VITRO STUDIES 
In Vitro Antioxidant Activity 
DPPH Radical Scavenging Activity 
DPPH and ABTS antioxidant activity were performed in synthesised compounds and they 
showed good antioxidant activity. The percentage inhibition and IC50 values are given in 
table 21 and DPPH radical scavenging activity of ascorbic acid and the synthesised 
compounds are shown in figure 51-52. 
 
Table 21 : Percentage inhibition and IC50 values of DPPH radical by Ascorbic acid and the 
synthesised compounds. 
Sample Concentration (µg/ml) % Inhibition 
IC50 (µg/ml) 
 
Standard(Ascorbic 
acid) 
1.0 3.37 
10.10 
1.5 5.08 
2.0 6.66 
2.5 7.60 
5.0 20.98 
10.0 50.36 
PZ-1 
33.33 22.81 
106.4 
66.66 35.87 
133.33 54.90 
200.00 63.11 
233.33 75.18 
333.33 82.12 
PZ-2 
33.33 35.83 
58.55 
66.66 51.47 
133.33 71.31 
200.00 82.88 
233.33 84.92 
333.33 90.53 
PZ-3 
1.0 6.71 
6.469 
2.0 7.81 
2.5 10.47 
5.0 27.45 
7.5 59.32 
10.0 85.22 
PZ-4 
33.33 45.64 
43.20 
66.66 55.57 
133.33 84.16 
200.00 86.82 
233.33 87.73 
333.33 91.00 
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Sample Concentration (µg/ml) % Inhibition IC50 (µg/ml) 
 
 
PZ-5 
33.33 27.40 68.72 
66.66 50.63 
133.33 65.25 
200.00 84.16 
233.33 86.82 
333.33 87.73 
 
PZ-6 
33.33 28.41 91.90 
66.66 40.73 
133.33 48.35 
200.00 67.14 
233.33 86.95 
333.33 89.05 
 
Figure 52: DPPH radical scavenging activity of Ascorbic acid and the synthesised 
compounds. 
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ABTS RADICAL SCAVENGING ACTIVITY 
Table 22: Percentage inhibition of ABTS radical by Ascorbic acid and the synthesised 
compounds. 
Sample Concentration (µg/ml) % Inhibition IC50 (µg/ml) 
Standard(Ascorbic 
acid) 
0.2 26.79 0.9374 
0.4 32.17 
0.6 34.94 
0.8 38.64 
1.0 43.49 
1.5 63.04 
2.0 80.22 
PZ-1 1.0 4.23 9.263 
1.5 6.04 
2.0 7.23 
2.5 8.66 
5.0 18.56 
10.0 55.66 
PZ-2 1.0 3.45 10.01 
1.5 5.36 
2.0 7.68 
2.5 8.32 
5.0 10.53 
10.0 51.65 
PZ-3 1.0 5.85 4.977 
1.5 6.86 
2.0 10.56 
2.5 13.65 
5.0 60.35 
10.0 72.88 
PZ-4 1.0 6.90 10.49 
1.5 8.46 
2.0 11.57 
2.5 14.66 
5.0 19.67 
10.0 51.84 
PZ-5 1.0 5.23 4.883 
1.5 7.34 
2.0 9.56 
2.5 15.85 
5.0 58.65 
10.0 75.65 
PZ-6 1.0 6.50 8.849 
1.5 8.46 
2.0 11.46 
2.5 16.45 
5.0 35.46 
10.0 52.46 
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Figure 53: ABTS radical scavenging activity of Ascorbic acid and the synthesised 
compounds. 
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IN VITRO STUDIES OF SYNTHESISED COMPOUNDS 
In order to confirm the activity of the synthesised compounds against colon cancer, the 
compounds were tested for their cytotoxicity against colon cancer cell lines(HT-29) and is 
given in table 23.Of the tested compounds, the compound PZ-5 was found to possess 
significant cytotoxicity against the HT-29 cell line with an IC50 value of 27.64µM and the HT 
29 cell inhibition of synthesised compounds were shown from fig.53-60.       
              Table 23: HT-29 Cell Line Inhibition of Synthesised Compounds 
 
Comp. 
 code 
 
Concentration 
 
% cell 
inhibition 
 
IC50 
Pz-1 
0.25 
2.5 
25 
50 
100 
0.084 
0.126 
2.763 
6.028 
25.409 
 
˃100 
Pz-2 
0.25 
2.5 
25 
50 
100 
0.084 
0.867 
1.339 
8.957 
29.259 
 
˃100 
 
 
Pz-3 
 
0.25 
2.5 
25 
50 
100 
 
0.627 
4.185 
31.268 
37.881 
52.867 
85.89 
 
Pz-4 
0.25 
2.5 
25 
50 
100 
0.085 
0.596 
1.233 
5.544 
16.367 
˃100 
 
Pz-5 
 
0.25 
2.5 
25 
50 
100 
 
13.436 
33.235 
46.672 
57.722 
59.690 
 
 
27.64 
 
 
Pz-6 
 
0.25 
2.5 
25 
50 
100 
 
 
 
0.098 
0.698 
2.689 
6.941 
26.846 
 
 
˃100 
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Figure 54: HT-29 Cell Line Inhibition By Compound PZ-1 
 
          
                          0.25 µM                                            2.5 µM      
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                                                     100µM 
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Figure 55: HT-29 Cell Line Inhibition By Compound PZ-2 
 
          
                      0.25 µM                                                    2.5 µM 
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                 Figure 56: HT-29 Cell Line Inhibition By Compound PZ-3 
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               Figure 57: HT-29 Cell Line Inhibition By Compound PZ-4 
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Figure 58: HT-29 Cell Line Inhibition By Compound PZ-6 
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Figure 59: HT-29 Cell Line Inhibition By Compound PZ-5 
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FIGURE 60: % CELL GROWTH OF COMPOUND PZ-3 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 61: % CELL GROWTH OF COMPOUND PZ-5 
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ACUTE ORAL TOXICITY STUDY 
Acute toxicity study was done according to OECD 423 guideline. No mortality was observed 
to a dose as 2000mg/kg p.o of (PZ-5) and the results showed that the compound could be 
used safely in the animals up to the dose of 2000mg/kg. Dose levels for the present study 
were chosen as 100mg/kg and 200mg/kg. 
 
Table 24: Effect of Vascular Endothelial Growth Factor Receptor Inhibitor (PZ-5) on 
Acute toxicity in Female Wistar Rat 
 
 
Sl 
no: 
Response Head Body Tail. 
Before. After. Before. After. Before. After. 
1 Alertness Normal Normal Normal Normal Normal Normal 
2 Grooming. Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response Normal Normal Normal Normal Normal Normal 
5 Pain response Normal Normal Normal Normal Normal Normal 
6 Tremor. Absent Absent Absent Absent Absent Absent 
7 Convulsion Absent Absent Absent Absent Absent Absent 
8 Righting reflux Normal Normal Normal Normal Normal Normal 
9 Gripping strength Normal Normal Normal Normal Normal Normal 
10 Pinna reflux Present Present Present Present Present Present 
11 Corneal reflux Present Present Present Present Present Present 
12 Writhing Absent Absent Absent Absent Absent Absent 
13 Pupils Normal Normal Normal Normal Normal Normal 
14 Urination Normal Normal Normal Normal Normal Normal 
15 Salivation Normal Normal Normal Normal Normal Normal 
16 Skin colour Normal Normal Normal Normal Normal Normal 
17 Lacrimation Normal Normal Normal Normal Normal Normal 
Results and Discussion  
 
Department of Pharmacology, KMCH College of Pharmacy  131 
 
EXPERIMENTAL DESIGN FOR DMH INDUCED COLON CANCER 
In the present study, DMH induced colon carcinoma in Sprague Dawley rats was 
performed.1,2-Dimethyl hydrazine(DMH) is a potent colon specific carcinogen and an 
alkylating agent can cause colon cancer which mimics human colon cancer  and is therefore, 
an ideal model for chemoprevention studies.  
 
Body weight analysis 
Body weight analysis was carried out on the basis of change in initial,intermediate  and final 
body weight of control (only DMH) and treated animals. At the time of tumour development, 
animal body weight will be reduced. The intraperitoneal administration of DMH to the rats 
showed significant decrease in the body weight when compared to normal control rats. In 
case of treatment groups after the administration of VEGFR2 inhibitor (PZ-5) at different 
doses(100mg/kg and 200mg/kg)  showed considerable prevention of weight loss when 
compared to DMH control rats. 
 
Table 25: Body weight analysis 
GROUPS 
(n =6) 
Normal Only DMH DMH+STD 
(5-FU-20mg/kg) 
DMH+PZ-5 
Low Dose 
(100 mg/kg) 
 
DMH+PZ-5 
High Dose 
(200mg/kg) 
 
Body 
weight 
(g) 
 
Initial 
day 161.2±2.833 148.0±8.571a,ns 142.5±7.671b,ns 158.3±0.9888b,ns 149.2±5.375b,ns 
Inter 
mediate 
day 212.5±5.353 155.8±2.088 a*** 204.3±4.264b*** 172.0±4.698b,ns 190.8±9.167b*** 
Final 
day 272.2±9.167 208.5±4.326 a*** 240.7±2.917b** 234.7±4.055b* 238.7±4.333b** 
a- only DMH compared with normal Group 
b- Group III, Group IV, Group V compared with only DMH. 
Ns-non significant 
 
 
Statistical comparison: One way ANOVA, followed by Tukey’s comparison was 
performed. All values are expressed as mean± SEM. Only DMH group was compared with 
Control group. Group III (DMH+STD), group IV (DMH+ PZ-5 Low dose), group V 
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(DMH+PZ-5 High dose), was compared with only DMH. (P<0.05-*, P<0.01-**, P<0.001- 
***) 
 
Figure 62: Body weight Analysis 
 
 
 
TUMOUR GROWTH 
The negative control (only DMH) group showed a significant tumor growth compared with 
normal due to tumour induction.The treatment with VEGFR2 inhibitor  (PZ-5-100mg/kg and 
200mg/kg i.p) showed considerable prevention of of tumor growth as  compared to DMH 
control rats and is given in figure 50. 
                                           
 
 
 
 
Figure 63: Tumour Growth 
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         Group I- Normal                                          Group II – Only DMH               
 
 
 
 
                                                    
 
Results and Discussion  
 
Department of Pharmacology, KMCH College of Pharmacy  134 
 
                                          
      Group III                  Group IV                          Group V 
     DMH + STD                    DMH + PZ-5                           DMH + PZ-5 
  (5-FU-20mg/kg)          (Low Dose-100mg/kg)       (High Dose -200mg/kg)                         
                  
 
 
 
 
 
ESTIMATION OF TUMEROGENESIS 
Estimation of tumerogenesis was carried out on the basis of changes in tumor burden and 
tumor weight is given in table 27. In this study, only DMH Group showed increase in tumour 
burden and tumour weight. The treatment with pyridazine derivative (PZ-5-100mg/kg and 
200mg/kg i.p) shows moderate decrease in tumour burden and tumour weight and is shown in 
figure 63 & 64. 
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Table 26: Estimation of tumour burden and tumor weight 
 
a- only DMH compared with normal Group 
b– Denotes when compared with only DMH.  
One way ANOVA, followed by Dunnet’s comparison was performed. Group III (DMH 
+STD), group IV (DMH + PZ-5 Low dose), group V (DMH + PZ-5 High dose), was 
compared with only DMH. (P<0.05-*, P<0.01-**, P<0.001- ***) 
Figure 64: Estimation of tumour burden 
 
 
 
Groups 
(n =6) 
 
Normal 
 
Only DMH 
 
DMH +STD 
(5-
FU,20mg/kg) 
 
DMH+ PZ-5 
Low Dose 
(100 mg/kg) 
 
 
DMH + PZ-5 
High Dose 
(200mg/kg) 
 
 
Tumour 
Burden 
(No.of 
polyps) 
          0 11.50±0.56a*** 5.167±0.47b*** 8.833±0.65b** 7.333±0.49b*** 
Tumour 
Weight 
(g) 
 
1.120±0.03 1.43±0.02 a*** 1.113±0.04b*** 1.275±0.03b* 1.181±0.05b*** 
Tumour 
(ACF) 
incidenc
e(%) 
__ 100% 
 
100% 
 
100% 
 
100% 
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                              Figure 65: Estimation of tumour weight 
 
ESTIMATION OF HAEMATOLOGICAL PARAMETERS 
In DMH control rats, a significant decrease in the RBC and Hb levels were shown as 
compared to normal control rats, but the WBC level was increased. In the PZ-5 treated 
groups, the levels of RBC and Hb were increased and there is a significant reduction in the 
WBC level.  
Data is expressed as Mean + SEM(n=6, animals in each groups) 
 
                   Table 27: Estimation of Haematological Parameters 
Groups 
(n =6) 
 
Normal 
 
 
Only DMH 
 
 
DMH +STD 
(5-FU, 
20mg/kg) 
 
DMH+ PZ-5 
Low Dose 
(100 mg/kg) 
 
 
DMH + PZ-5 
High Dose 
(200mg/kg) 
 
RBC 
(1x10 6 / L) 
7.823±0.1299a*** 
 
6.148±0.04799
b*** 
7.633±0.1275b
*** 
7.008±0.2298b*
** 
7.743±0.08811b
*** 
WBC 
(1x10 3/ L) 
10.08±0.4223a*** 
 
14.35±0.1310b
*** 
10.08±0.5469b
*** 
12.95± 
0.1302b* 
10.61± 
0.3480b*** 
Hb 
(g/dl) 
14.42±0.4643a*** 
 
9.850±0.1803b
*** 
14.00±0.4648 
b*** 
13.15±0.6464 
b*** 
13.72±0.4792 
b*** 
 
             a-only DMH compared with normal Group, 
b- Group III, Group IV, Group V compared with only DMH. 
Statistical comparison: One way ANOVA, followed by Dunnet’s comparison was 
performed. Only DMH group was compared with Normal group. Group III (DMHV+STD), 
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group IV (DMH +PZ-5 Low dose), group V (DMH+ PZ-5 High dose), was compared with 
only DMH. 
(P<0.05-*, P<0.01-**, P<0.001- ***) 
 
Figure 66: Enumeration of RBC 
 
 
Figure 67: Enumeration of WBC 
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                         Figure 68: Estimation of Haemoglobin 
 
      
 
 
              
 ESTIMATION OF SERUM BIOCHEMICAL PARAMETERS 
Serum biochemical levels estimation is one the major diagnosing tool to confirm liver 
diseases.The parameters include ALP, SGOT, SGPT, total protein and creatinine and these 
parameters are considered as the tumour marker in this study.A significant increased serum 
biochemical parameter levels were observed in the DMH control rats when compared to 
normal control rats. Rats treated with PZ-5 showed significantly lower biochemical levels 
when compared to DMH control.  
 
Data is expressed as Mean +SEM .(n=6, animals in each groups) 
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Table 28: Estimation Of Serum Biochemical Parameters 
Groups 
(n =6) 
 
Only DMH 
 
 
Normal 
 
 
 
DMH +STD 
(5-FU,  
20mg/kg) 
 
 
DMH+ PZ-5 
Low Dose 
(100 mg/kg) 
 
 
DMH + PZ-5 
High Dose 
(200mg/kg) 
 
ALP 
(U/L) 
174.3±2.860 
 
85.67±2.044a**
* 
105.7±2.578b*** 
 
144.0±6.608 
b*** 
112.8±1.641 
b*** 
SGOT 
(U/L) 99.33±2.565 
 
46.17±1.249 
a*** 
 
61.67±2.319b*** 
 
82.83±4.735 
b*** 
62.17±2.120 
b*** 
SGPT 
(U/L) 
 
93.17±1.376 
 
26.67±1.706 
a*** 
38.00±1.125 
b*** 
56.33±5.077 
b*** 
41.00±1.713 
b*** 
Creatinin
e 
(mg/dl) 
0.8667±0.0666
7 
0.4667±0.0500 
a*** 
0.4833±0.0307
3 b*** 
0.6000±0.0365
1 b** 
0.5000±0.0447
2 b*** 
Total 
protein 
(mg/dl) 
7.833±0.1382 
 
4.117±0.08724 
a*** 
4.700±0.1183 
b*** 
7.050±0.2405 b* 
 
6.850±0.2553 
b** 
 
    a-only DMH compared with normal Group 
    b- Group III, Group IV, Group V compared with only DMH. 
    ns -nonsignificant 
Statistical comparison: One way ANOVA, followed by Dunnet’s comparison was 
performed. Only DMH group was compared with Normal group. Group III (DMH+STD), 
group IV (DMH+PZ-5 Low dose), group V (DMH+ PZ-5 High dose), was compared with 
only DMH. (P<0.05-*,  P<0.01-**, P<0.001- ***) 
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Figure 69:Estimation of Serum Biochemical Parameters 
 
    
 
     
 
 
 
ESTIMATION OF INVIVO ANTIOXIDANT ACTIVITY  
Living organisms have developed several effective mechanisms to get protection from the 
reactive oxygen species. In vivo antioxidant system can be divided into enzymatic and non 
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enzymatic. The enzymatic defence system includes superoxide dismutase (SOD), catalase 
(CAT), glutathione peroxidise (GPx) and non enzymatic defence system includes reduced 
glutathione (GSH) and invivo antioxidant levels in colon was shown in figure.  
Super Oxide Dismutase 
The cells containing this enzyme scavenges superoxide ion and prevents its accumulation so 
that cells are protected from oxidative stress. SOD catalyses this dismutation of superoxide in 
which one O2* is oxidized to O2 while the other is reduced to H2O2. The formed H2O2 is able 
to damage the cellular components and are instantly removed by enzymes like catalase and 
GPx. A significant decrease in SOD levels was observed in DMH control rats when 
compared to normal control rats. The levels get increased in the rats treated with compound 
PZ-5 and 5-Fluorouracil  when compared to SOD levels in DMH control rats. 
Catalase 
Oxidative stress has a major role in carcinogenesis. The catalase enzyme is an endogenous 
antioxidant enzyme that neutralizes reactive oxygen species by converting H2O2 into H2O and 
O2. Among the other antioxidant enzymes, including superoxide dismutase and glutathione 
peroxidase, catalase is an elementary defense against oxidative stress. In DMH control rats, a 
significant decreased level of catalase was observed as compared to normal control rats. The 
compound PZ-5 and 5-Fluorouracil  treated groups showed significant increase in catalase 
levels when compared to DMH control rats. 
Reduced Glutathione 
It prevents free radical induced oxidation of SH groups of various proteins to disulfide 
derivatives. It also protects haemoglobin from getting oxidized by H2O2. A significant 
decrease in the GSH levels was observed in the DMH control rats when compared to normal 
control rats. Rats treated with PZ-5 and 5-Fluorouracil showed significantly higher GSH 
levels when compared to DMH control rats. 
Glutathione Peroxidase 
The biochemical function of GPx involves the reduction of lipid hydroperoxides to their 
alcohols and to reduce free hydrogen peroxide to water. Thus, it protects the cell from 
oxidative damage. The DMH control rats showed significant lower GPx levels when 
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compared to the normal control rats. The compound PZ-5 and 5-Fluorouracil treated rats 
showed significant higher GPx levels when compared to DMH control rats. 
Lipid Peroxidation 
Lipid peroxidation indicates the oxidative degradation of lipids in which the free radicals 
steals electrons from the lipids in the cell membrane and leads to cell damage. This process 
proceeds by a free radical chain reaction mechanism. Radical reaction consists of initiation, 
propagation and termination processes. A significant increased level of LPx was observed in 
the DMH control rats when compared to normal control rats. The compound PZ-5 and 5-
Fluorouracil treated rats showed significant decreased LPx levels when compared to DMH 
control rats. 
Mitochondrial TCA-cycle enzymes 
As mitochondria plays a critical role in bioenergetics, anabolic and cell death pathways which 
range from high tissue-specific conditions to generalized whole-body disorders including 
cancer. Several common features of established tumour cells can directly or indirectly result 
from mitochondrial deregulation. Mitochondria may be implicated in early tumerogenesis. 
 
Data is expressed as Mean +SEM .(n=6, animals in each groups) 
Table 29: In vivo antioxidant levels in Colon 
Groups Antioxidant enzymes(Colon) 
SOD(unit/min/m
g protein) 
CATALASE 
 ( μmol 
of H2O2 
consumed/min/ 
mg 
protein) 
GSH 
(Glutathione 
μg/mg) 
GPx(nmol of 
glutathione 
oxidized/min/mg 
protein) 
LPO (nmol of 
MDA/mg 
protein) 
Normal 5.533±0.07149 41.83±0.7923 19.74±0.3712 5.280±0.2251 
 
 
 
7.607±0.3664 
Only DMH 2.150±0.1118a*** 22.67±1.054 a*** 11.21±0.1727a**
* 
2.773±0.1098a*** 
 
 
 
25.77±0.3831 
a*** 
DMH +STD (5-
FU, 20mg/kg) 
 
5.133±0.1706b*** 39.17±0.7032 b*** 18.94±0.2929b**
* 
4.763±0.1173b*** 
 
 
 
8.998±0.2671 
b*** 
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DMH+PZ-5 
Low Dose 
(100 mg/kg) 
 
3.000±0.1317b*** 34.83±1.493 b*** 15.30±0.5102b**
* 
3.642±0.1259b*** 
 
 
 
12.64±0.5315 
b*** 
DMH+PZ-5 
High Dose 
(200 mg/kg) 
 
4.983±0.09098b*
** 
37.83±0.9458 b*** 17.80±0.2452b**
* 
4.607±0.1028b*** 
 
 
 
9.632±0.4543 
b*** 
a- only DMH compared with normal Group 
b- Group III, Group IV, Group V compared with only DMH. 
ns –non significant 
 
Statistical comparison: One way ANOVA, followed by Dunnet’s comparison was 
performed. Only DMH group was compared with Normal group. Group III (DMH+STD), 
group IV (DMH+PZ-5 Low dose), group V (DMH + PZ-5 High dose), was compared with 
only DMH. (P<0.05-*, P<0.01-**, P<0.001- ***) 
 
 
 
 
Figure 70: In vivo antioxidant levels in Colon 
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Estimation of Total protein- (Liver) 
Table 43: shows total protein levels in Liver 
Data is expressed as Mean +SEM .(n=6, animals in each groups) 
 
Table 30: Estimation of Total protein 
GROUPS 
(n =6) 
DMH Only Normal DMH +STD 
(5-FU,20mg/kg) 
DMH + PZ-5 
LOW DOSE 
(100 mg/kg) 
 
DMH+ PZ-5 
HIGH DOSE 
(200 mg/kg) 
 
Total 
protein 
(mg/100mg 
tissue) 
2.800±0.2280 
 
 
5.317±0.4658a*** 
 
 
4.800±0.2236b*** 
 
 
4.100±0.1592b** 
 
 
4.583±0.1138b*** 
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a- only DMH compared with Normal Group 
       b- Group III, Group IV, Group V compared with only DMH 
Statistical comparison: One way ANOVA, followed by Dunnet’s comparison was 
performed. Only DMH group was compared with Control group. Group III (DMH+STD), 
group IV (DMH+ PZ-5 Low dose), group V (DMH+ PZ-5 High dose), was compared with 
only DMH.  
(P<0.05-*, P<0.01-**, P<0.001- ***) 
Figure 71: Estimation of Total protein 
 
 
ESTIMATION OF TCA CYCLE ENZYME  
Estimation of succinate dehydrogenase 
Succinate dehydrogenase 
The Succinate Dehydrogenase level was found to be significantly decreased in DMH control 
rats when compared to normal control rats. Rats treated with compound PZ-5 and 5-FU 
showed significantly higher Succinate Dehydrogenase levels when compared to DMH control 
rats 
Table 31:: shows Succinate dehydrogenase levels in Liver 
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GROUPS 
(n =6) 
NORMAL ONLY DMH DMH+STD DMH +PZ-5 
Low Dose 
(100 mg/kg) 
 
DMH+ PZ-5 
High Dose 
(200mg/kg) 
 
 
Succinate 
Dehydrogenase 
(µmol of 
succinate 
oxidised/min/m
g protein) 
218.8±0.945
8 
 
 
 
163.5±1.727a**
* 
 
 
 
188.3±1.054b**
* 
 
 
 
175.7±2.352b
* 
 
 
 
186.5±1.258b**
* 
 
 
 
 
All values are expressed as mean± S.E.M; (n=6) animals in each group. 
Statistical comparison: One way ANOVA, followed by Dunnet’s comparison was 
performed. Only DMH group was compared with Control group. Group III (DMH+STD), 
group IV (DMH+ PZ-5 Low dose), group V (DMH+ PZ-5 High dose), was compared with 
only DMH.  
Figure 72:Estimation of succinate dehydrogenase 
 
 
 
                                     HISTOPATHOLOGICAL ANALYSIS 
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Histopathological analysis of tumours of various groups revealed that only 
DMH group shows high amount of infiltration whereas the level of infiltration 
for standard was less when compared with that of test compound PZ-5. 
Figure 73: Histopathology of Colon tumours 
GROUP –I Normal 
 
                                    
    10x shows Colonic mucosa                                                40x shows Colonic mucosa  
 
 
 GROUP –II Only DMH 
 
                          
10x shows Colonic mucosa with dysplastic changes.40x shows mild dysplastic cells with 
occasional mitosis      
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GROUP – III DMH+ STD 
 
                     
10x shows Colonic mucosa with mild inflammation.40x shows normal mucosa with  
inflammatory infiltrates in the lamina propria  
  
  
 
 
 
     GROUP – IV DMH+ Test compound PZ-5 Low Dose 100 mg/kg 
 
                     
10x shows normal Colonic mucosa with muscular layer and submucosa.40x shows 
lamina propria shows mild inflammation  
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GROUP –V DMH + Test Compound PZ-5 High Dose 200 mg/kg 
 
                       
  10x shows normal mucosa,sub mucosa_and muscular layer. 40x shows Colonic mucosa 
 with infiltrates  
 
Figure 74:  Immunohistochemical Reaction 
 
GROUP – II Only DMH 
              
                     10x                                                      40x 
 COX -2:  Cytoplasmic postivity in inflammatory cells (2+)  
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GROUP – III DMH+ Std 
(5-FU-20mg/kg) 
 
                      
                     10x                                                      40x 
             COX -2:  Cytoplasmic postivity in inflammatory cells (2+)  
 
GROUP – IV (DMH+PZ-5) 
Low Dose 100 mg/kg 
 
                    
                     10x                                                      40x 
 
COX -2:  Cytoplasmic postivity in inflammatory cells (2+) 
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GROUP – V (DMH+PZ-5) 
High Dose 200 mg/kg 
 
                         
                     10x                                                      40x 
   
COX -2:  Cytoplasmic postivity in inflammatory cells (2+) 
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7. DISCUSSION 
Cancer has reached epidemic proportions globally and accounts for 12 million cases 
worldwide and 7.9 million deaths. The current challenges of anticancer drug development 
include the significant time and cost involvement, and the low success rates. These issues 
lead to increasing efforts of the pharmaceutical industry toward increasing the 
effectiveness of the drug discovery and development process to minimize failure of drug 
candidates at later stages of development. It also includes development of high 
throughput preclinical screening methods (computational molecular modeling 
techniques) and biological assays with greater specificity and predictability. The 
advanced search for newer avenues in the treatment of cancer has led research into the 
elucidation of signaling pathways.
[29]
  
            The recent growth in molecular sciences and the advances in genomics and 
proteomics paradigms the anticancer drug discovery towards molecularly targeted 
therapeutics. 
                  The target selection is a crucial step in modelling, among these targets, 
angiogenesis is one of the critical processes that affect growth and development of 
cancerous cells. The Vascular endothelial growth factor receptor(VEGF) are selected as 
target protein,which is one of the most potent angiogenic factors. Vascular endothelial 
growth factor (VEGF) signaling through VEGF receptor 2(VEGFR 2) has been 
implicated to play a key role in the regulation of tumor angiogenesis. VEGF is a 
homodimeric cytokine that is expressed in atleast four splice-variant forms of 121-206 
residues. Over expressed VEGF correlates with poor prognosis and clinical stage in solid 
tumor patients. Therefore,VEGF/VEGFR2 signaling is an attractive target for the 
treatment of cancer.
[24] 
                    During the course of pharmaceutical development of novel VEGFR2 
inhibitors, pharmacophore and docking based in silico studies are efficiently used to 
improve the discovery of lead identification and optimization, which is followed by the 
synthesis of lead compound derivatives and their biological evaluation. In silico 
Molecular modelling studies will lead to invention of a potent molecule in less time with 
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reduction in the usage of chemicals and animals, it will be a process of In-cerebro-In-
silico and chemico approach of drug designing. 
                         Pyrazolopyridazine have garnered attention due to its wide variety of 
biological activities which are structural analogues of many purine nucleosides moreover 
it was identified through high throughput screening as a potent inhibitor of VEGFR2 and 
has remarkable anticancer activity. It is also found to be cytotoxic against a wide variety 
of cancer cell lines which prompted us to select the nucleus. 
 
Lead Optimisation
[11] 
  Lead optimisation was performed for the designed 54 Pyrazolo benzpyridazine 
derivatives by Molispiration software which showed that all compounds followed 
Lipinski’s rule of five. Compounds that satisfy these rules are considered as drug like and 
were analysed for their ADMET toxicity. Statistics reports show that a lot of drug 
candidates are failed during clinical tests because of the problems related to ADME, and 
nowadays researchers consider ADME properties as important condition to choose 
compounds as drug candidates. Numerous in vitro methods have been used in the drug 
selection process for assessing the intestinal absorption of drug candidates. Among them, 
Caco-2 cell model has been recommended as a reliable in vitro model for the prediction 
of oral drug absorption. 
 Predicting human intestinal absorption of drugs is very important for identify 
potential drug candidate. In PreADMET can predict percent human intestinal 
absorption (%HIA). Human intestinal absorption data are the sum of 
bioavailability and absorption evaluated from ratio of excretion or cumulative 
excretion in urine, bile and feces. 
 Blood-Brain Barrier (BBB) penetration is represented as BB = [Brain]/[Blood], 
where [Brain] and [Blood] are the steady-state concentration of radiolabeled 
compounds in brain and peripheral blood. Predicting BBB penetration means 
predicting whether compounds pass across the blood-brain barrier. This is crucial 
in pharmaceutical sphere because CNS-active compounds must pass across it and 
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CNS-inactive compounds mustn’t pass across it in order to avoid of CNS side 
effects. 
From all the above parameters studied, it was found that compound PZ-5 is best among 
all the compounds designed.  
Analysis of the many available crystal structures of kinase/ inhibitor complexes reveals 
the existence of conserved interactions that appear to be determinant for the recognition 
of small heterocyclic molecules by the ATP (cofactor) binding site of this class of 
enzymes. Prominent among these are hydrogen bond interactions that inhibitors make 
with the backbone of the amino acid stretch that connects the kinase N- and C-terminal 
domains, the so called ‘hinge’ loop. In particular, for VEGFR2, at least one hydrogen 
bond with hinge residue Cys 919 is observed in all reported crystal structures. These 
hydrogen bonds position the inhibitors in an orientation that allow them to make multiple 
favourable contacts with the side chains of hydrophobic residues that normally form the 
environment of the adenine ring of ATP in the pocket. In the case of VEGFR2, these 
residues include Leu1035A, Ala866A,Val916A and Lys868A.Our strategy to find new 
VEGFR2 inhibitors is based on the design of molecular scaffolds targeting ATP 
interactions so we used an X-ray crystal structure of VEGFR2 (PDB ID: 3VO3) to design 
pyrazolo benzpyridazine ligands. 
A library of 54 ligands were virtually designed and docked to the VEGF protein. Based 
on the docking scores, amino acid interactions, drug likeliness and ADME prediction, 
feasibility of synthesis, 6 compounds were selected for synthesis.  
Synthesis of the compounds involves the following steps: 
       Step 1: Synthesis of Ethyl 3 –oxo-2-(2-substituted phenylhydrazinylidene) butanoate. 
       Step 2: Synthesis of 3-Acetyl benzpyridazine-4(1H)-one derivatives. 
       Step 3: Synthesis of Pyrazolo benzpyridazine derivatives 
Physical parameters like percentage yield, molecular weight, molecular formula, melting 
point, logP and Rfvalue of the synthesized compounds were determined. The final 
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compounds were in moderate to higher yields. The percentage yield was found to be in 
the range of 65 – 90 %. 
The structures of the synthesized compounds were confirmed by IR, NMR, and mass 
spectral analysis.IR Spectrum of the synthesized compounds showed the characteristic 
absorption band at 2911-2926.93 cm
-1
,3162.69-3484.26 cm
-1
, 1588.59-1629.55 cm
-
1
,1045.71-1249.16 cm
-1
,1405.37-1667 cm
-1 
,2926-3162.69 cm
-1 
arising from stretching 
vibration of bands (C-H, N-H, N=N, C-N, C=N, Aromatic C-H respectively), 1530.24 
cm
-1
,1145.03 cm
-1 
,3228.74-3302.02 cm
-1
 ,1096 cm
-1 
due to NO2 stretching, C-F 
stretching, C-SO2NH2 stretching and C-Cl stretching respectively which confirms the 
chemical structure of the compounds synthesized.PMR spectra of the synthesized 
compounds derivatives shows peaks ranging from 10.69-11.61ppm,7-7.99 and 2.1-
2.3ppm which is characteristic of H in NH, Aromatic H  and H in CH3 respectively. Thus 
the proton magnetic spectrum of the compound was in full agreement with its molecular 
formula, with regard to proton count and the chemical shift also.The Mass Spectral 
analysis of the synthesized compounds PZ-1 and PZ-5 were performed, and the mass 
spectrum of the compound was in agreement with its molecular weight. 
DPPH and ABTS in vitro antioxidant activity were performed in synthesised compounds 
and they showed good antioxidant activity. The effect of antioxidants on DPPH and 
ABTS was thought to be due to their hydrogen donating ability. The free radical 
scavenging activity of the extract was estimated by comparing the % inhibition of 
synthesized compounds(PZ-1 to PZ-6) with standard ascorbic acid. The activity was 
found to be increased in a dose dependent manner.  
In order to confirm the activity of the synthesized compounds against colon cancer, the 
compounds were tested for their cytotoxicity against colon cancer cell lines (HT-29). All 
the compounds tested were found to possess cytotoxicity against the cell lines. Of the 
tested compounds, the compound PZ-5 was found to possess significant cytotoxicity 
against the HT-29 cell line with an IC50 value of 27.64 µM.  
Based on the IC50 value and the docking scores, compound PZ-5 was selected for further 
animal studies against DMH induced colon carcinoma on male Sprague Dawley rats. 
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Acute toxicity study was done according to OECD 423 guideline. No mortality was 
observed to a dose as 2000mg/kg p.o of (PZ-5) and the results showed that the compound 
could be used safely in the animals up to the dose of 2000mg/kg. Dose levels for the 
present study were chosen as 100mg/kg and 200mg/kg.  
Experimental colon cancer induced by DMH in rats mimics human colon cancer  and is 
therefore, used to evaluate anticancer property of drugs.  In which, DMH will be 
converted to diazonium ions,azoxymethane(AOM) and methylazoxymethanol(MAM) in 
presence of NAD
+ 
-dependent dehydrogenase enzyme.These intermediates alkylate 
colonic mucosal DNA and results in oxidative stress followed by delayed repair of 
damaged DNA leads to the accumulation of multiple mutations such as Apc,K-ras,b-
catenin and thus leads to susceptibility of specific adenocarcinoma of colon. 
 
In this study, administration of DMH to the female Sprague Dawley rats produced 
significant colon tumour compared to normal control. 
At the time of tumour development, animal body weight will be reduced. The 
intraperitoneal administration of DMH to the rats showed significant decrease in the body 
weight when compared to normal control rats. In the case of treatment groups after the 
administration of PZ-5 at different doses showed considerable prevention of weight loss 
when compared to DMH control rats. 
Haematological Parameters 
In DMH control rats, a significant decrease in the RBC and Hb levels were shown as 
compared to normal control rats. But the WBC level was increased. In the PZ-5 treated 
groups, the levels of RBC and Hb were increased and there is a significant reduction in 
the WBC level.  
Biochemical Parameters 
The biochemical parameters like SGPT, SGOT, urea, serum creatinine were estimated to 
detect the effect of PZ-5 on liver and kidney function. In the present study, a significant 
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increased serum ALP levels was observed in the DMH control rats when compared to 
normal control rats. Rats treated with PZ-5 showed significantly lower ALP levels when 
compared to DMH control. The other parameters were found to be non-significant when 
compared to DMH control rats.  
In vivo antioxidants 
Living organisms have developed several effective mechanisms to get protection from 
the reactive oxygen species. The antioxidant defense mechanisms of the body include 
enzymes such as SOD,GSH, catalase and GPx. 
Super Oxide Dismutase 
The cells containing this enzyme scavenges superoxide ion and prevents its accumulation 
so that cells are protected from oxidative stress. SOD catalyses this dismutation of 
superoxide in which one O2* is oxidized to O2 while the other is reduced to H2O2. The 
formed H2O2 is able to damage the cellular components and are instantly removed by 
enzymes like catalase and GPx. A significant decrease in SOD levels was observed in 
DMH control rats when compared to normal control rats. The levels get increased in the 
rats treated with compound PZ-5 and 5-Fluoro uracil when compared to SOD levels in 
DMH control rats. 
Catalase 
Oxidative stress has a major role in carcinogenesis. The catalase enzyme is an 
endogenous antioxidant enzyme that neutralizes reactive oxygen species by converting 
H2O2 into H2O and O2. Among the other antioxidant enzymes, including superoxide 
dismutase and glutathione peroxidase, catalase is an elementary defense against oxidative 
stress. In DMH control rats, a significant decreased level of catalase was observed as 
compared to normal control rats. The compound PZ-5 and 5-Fluorouracil treated groups 
showed significant increase in catalase levels when compared to DMH control rats. 
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Reduced Glutathione 
 It prevents free radical induced oxidation of SH groups of various proteins to disulfide 
derivatives. It also protects haemoglobin from getting oxidized by H2O2. A significant 
decrease in the GSH levels was observed in the DMH control rats when compared to 
normal control rats. Rats treated with PZ-5 and 5-Fluorouracil showed significantly 
higher GSH levels when compared to DMH control rats. 
Glutathione Peroxidase. 
The biochemical function of GPx involves the reduction of lipid hydroperoxides to their 
alcohols and to reduce free hydrogen peroxide to water. Thus, it protects the cell from 
oxidative damage. The DMH control rats showed significant lower GPx levels when 
compared to the normal control rats. The compound PZ-5 and 5-Fluorouracil treated rats 
showed significant higher GPx levels when compared to DMH control rats. 
Lipid Peroxidation 
Lipid peroxidation indicates the oxidative degradation of lipids in which the free radicals 
steals electrons from the lipids in the cell membrane and leads to cell damage. This 
process proceeds by a free radical chain reaction mechanism. Radical reaction consists of 
initiation, propagation and termination processes. A significant increased level of LPx 
was observed in the DMH control rats when compared to normal control rats. The 
compound PZ-5 and 5-FU treated rats showed significant decreased LPx levels when 
compared to DMH control rats. 
Mitochondrial TCA-cycle enzymes 
As mitochondria plays a critical role in bioenergetics, anabolic and cell death pathways 
which range from high tissue-specific conditions to generalized whole-body disorders 
including cancer. Several common features of established tumour cells can directly or 
indirectly result from mitochondrial deregulation. Mitochondria may be implicated in 
early tumerogenesis. 
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Succinate dehydrogenase 
The Succinate Dehydrogenase level was found to be significantly decreased in DMH 
control rats when compared to normal control rats. Rats treated with compound PZ-5 and 
5-FU showed significantly higher Succinate Dehydrogenase levels when compared to 
DMH control rats. 
Histopathological analysis 
Histopathological analysis of tumours of various groups revealed that DMH control 
group shows dysplastic cells with occasional mitosis and high amount of infiltration 
whereas the level of infiltration for standard was less when compared with that of test 
compound PZ-5. 
Immunohistochemistry analysis  
COX-2 plays a pivotal role throughout oncogenesis mainly in colon carcinoma and is 
induced in response to growth factors. Immunohistolochemical analysis of colon tumours 
using COX2 as marker was  performed. DMH control rats shows Cytoplasmic postivity 
in inflammatory cells (3+) whereas the standard and PZ-5 (high dose) shows Cytoplasmic 
postivity in inflammatory cells(1+). 
Conclusion 
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8. CONCLUSION 
            In conclusion, some novel substituted Pyrazolo benzpyridazine 
derivatives have been designed and docked into target protein Human VEGFR2 
(PDB ID 3VO3). Based on the docking score, feasibility of synthesis and 
chemical availability, six top ranked compounds with good dock score and 
binding interactions with amino acid cys919 were synthesized and 
characterized for their physical constants such as molecular formula, molecular 
weight, melting point, Rf value, and their chemical structures were confirmed 
by FT-IR, 1H-NMR, Mass spectroscopy. The synthesized compounds were 
evaluated for its in vitro and in vivo anticancer activity. All derivatives 
demonstrated mild to moderate in-vivo cytotoxic activity against HT-29 cell 
lines by MTT assay, out of which compound PZ-5 exhibited promising activity 
against HT-29 cell lines. In in-vivo anticancer screening studies of Compound 
PZ-5,it exhibited moderate activity against DMH induced colon carcinoma in 
Sprague Dawley Rats when compared with that of the standard 5-Fluorouracil. 
         Taking into account the significant activities of the examined compounds, 
it is believed that further optimization of these identified chemical leads can 
probably lead to the development of more active molecules. Further studies on 
its possible mechanism against HT-29 cell lines as well as against various other 
cell lines may also reveal significant activity against a wide variety of cancers.  
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